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ABSTRACT 
Gemcitabine (2’-2’-difluoro-deoxycytidine) is an intravenously administered 
nucleoside analogue used in the treatment of various solid tumor cancers. While oral 
gemcitabine administration would offer a more patient-friendly, less complex, and less 
expensive alternative to intravenous administration, the clinical utility of oral gemcitabine 
administration is hindered by a low oral bioavailability of approximately 10%. This low 
oral bioavailability was previously believed to be the result of gemcitabine’s low intestinal 
permeability and oral absorption, followed by significant presystemic metabolism by the 
enzyme cytidine deaminase (CDA).  
In one study, we sought to define the mechanisms of gemcitabine intestinal 
permeability, the potential for saturation of intestinal uptake, and the transporter(s) 
responsible for mediating the oral absorption of drug using in situ single-pass intestinal 
perfusions in mice. Concentration-dependent studies were performed for gemcitabine over 
0.5 to 2000 µM, along with studies of 5 µM gemcitabine in a sodium-containing buffer ± 
thymidine (which can inhibit concentrative (i.e., CNT1 and CNT3) and equilibrative (i.e., 
ENT1 and ENT2) nucleoside transporters) or dilazep (which can inhibit ENT1 and ENT2), 
or in a sodium-free buffer (which can inhibit CNT1 and CNT3). Our findings demonstrated 
that gemcitabine was, in fact, a high-permeability drug in the intestine at low 
concentrations, that jejunal uptake of gemcitabine was saturable and mediated almost 
exclusively by nucleoside transporters, and that jejunal flux was mediated by both high-
 xix 
affinity, low-capacity (Km = 27.4 µM, Vmax = 3.6 pmol/cm2/s) and low-affinity, high-
capacity (Km = 700 µM, Vmax = 35.9 pmol/cm2/s) transport systems. Thus, CNT(s) and 
ENT(s) at the apical membrane allow for gemcitabine uptake from the lumen to enterocyte, 
whereas ENT(s) at the basolateral membrane allow for gemcitabine efflux from the 
enterocyte to portal venous blood. These results further show that systemic exposure 
following oral gemcitabine administration is limited by extensive CDA-mediated 
presystemic metabolism and potentially by saturation of nucleoside transporter-mediated 
intestinal uptake following oral administration of large doses (i.e., doses which generate 
saturating gemcitabine concentrations in the intestinal lumen). 
 A subsequent study evaluated the in vivo performance of a peptide transporter 1 
(PEPT1)-targeted amino acid ester prodrug of gemcitabine, 5’-L-valyl-gemcitabine (V-
Gem), developed to increase gemcitabine’s oral bioavailability. V-Gem was previously 
shown to be a substrate of the intestinally expressed PEPT1 and stable against CDA-
mediated metabolism. However, earlier studies did not evaluate the in vivo oral 
performance of V-Gem as compared to parent drug. Therefore, we evaluated the 
pharmacokinetics and in vivo oral absorption of gemcitabine and V-Gem following 
intravenous and oral administrations in mice. These studies revealed that V-Gem 
undergoes rapid systemic elimination (half-life < 1 min) and has a low oral bioavailability 
(< 1%). Most importantly, the systemic exposure of gemcitabine was not different 
following oral administration of equimolar doses of gemcitabine (gemcitabine 
bioavailability of 18.3%) and V-Gem (gemcitabine bioavailability of 16.7%). Single-pass 
intestinal perfusions with portal blood sampling in mice revealed that V-Gem undergoes 
extensive activation (i.e., conversion to gemcitabine) in intestinal epithelial cells and that 
 xx 
gemcitabine undergoes first-pass metabolism in intestinal epithelial cells. Thus, 
formulation of gemcitabine as the prodrug V-Gem does not increase systemic gemcitabine 
exposure following oral dosing, due, in part, to the metabolic instability of V-Gem in 
intestinal epithelial cells. These findings suggest that future development of gemcitabine 
prodrugs for oral administration should focus on prodrugs with high intestinal 
permeability, high presystemic stability, and complete in vivo conversion to gemcitabine.   
 1 
CHAPTER 1  
Research Objectives 
 Gemcitabine is a nucleoside analog with regulatory approval for use in the 
treatment of pancreatic, lung (in combination with cisplatin), breast (in combination with 
paclitaxel), and ovarian (in combination with carboplatin) cancers [1]. Furthermore, 
gemcitabine is extensively used off-label in combination with other medications and for 
the treatment of other solid tumors [2]. Gemcitabine is utilized clinically for both its 
cytotoxic (i.e., ability to kill cancer cells) and radiosensitizing (i.e., ability to make cancer 
cells more sensitive to radiation therapy) properties [3, 4]. Generally, gemcitabine is 
administered to patients via a 30-minute intravenous infusion, once per week at a dose of 
1,000 – 1,250 mg/m2 [1]. Although not currently available, an orally administrable 
formulation would benefit patients, providers, and payers by making gemcitabine 
administration more patient-friendly, safer, and cheaper. Furthermore, orally administrable 
gemcitabine would enable a variety of dosing regimens which may increase the efficacy 
and/or reduce the toxicity associated with gemcitabine therapy but are difficult to 
implement when the drug is administered intravenously (e.g., frequent low dose 
administration) [5, 6]. 
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 Despite these advantages associated with oral administration, the clinical utility of 
orally administered gemcitabine is hampered by a low oral bioavailability of approximately 
10% [7]. Although few studies have explored the mechanistic basis of this low oral 
bioavailability, it is generally believed to be a result of incomplete absorption from the 
gastrointestinal tract and first-pass metabolism in the intestinal epithelium and/or liver by 
the enzyme cytidine deaminase [7, 8]. While various formulation strategies may be 
employed to increase intestinal absorption and/or reduce first-pass metabolism, a better 
understanding of the barriers limiting gemcitabine’s oral bioavailability is necessary for 
the rational application of these strategies to the design and development of gemcitabine 
formulations with increased oral bioavailability. 
Specifically, although gemcitabine is widely considered to have low intestinal 
permeability, gemcitabine’s intestinal absorption has not previously been systematically 
characterized. Furthermore, preliminary studies examining gemcitabine absorption utilized 
in vitro cell lines (e.g., Caco-2 cells) which have low expression levels of intestinally 
expressed nucleoside transporters known to transport gemcitabine [8-11] and do not 
replicate important physiological aspects of intestinal drug absorption (e.g., intact blood 
supply). Thus, studies which enhance the understanding of gemcitabine’s intestinal 
absorption and its role in limiting oral bioavailability may provide critical information for 
the future development of orally administrable gemcitabine. 
 One such strategy to increase gemcitabine’s oral bioavailability, formulating 
gemcitabine as the amino acid ester prodrug 5’-L-valyl-gemcitabine (V-Gem), may both 
increase gemcitabine’s intestinal absorption and reduce gemcitabine’s first-pass 
metabolism. First, while gemcitabine was widely believed to undergo limited intestinal 
 3 
absorption, V-Gem was developed to act as a substrate of the intestinal uptake transporter 
peptide transporter 1 (PEPT1) (i.e. a PEPT1-targeted prodrug) [12]. PEPT1 is a high-
capacity, low-affinity transporter extensively expressed on the apical membrane of 
intestinal enterocytes and has been successfully targeted to increase the intestinal uptake 
of low-permeability drugs via formation of PEPT1-targeted prodrugs. Such prodrugs, 
which are typically formulated by attaching an amino acid or dipeptide to the parent 
compound via an ester bond, undergo PEPT1-mediated intestinal uptake and are 
subsequently activated, liberating the parent compound [13]. Thus, as V-Gem was verified 
in vitro to be a PEPT1 substrate, it is expected to undergo increased intestinal absorption 
[10, 12]. Next, while gemcitabine undergoes cytidine deaminase-mediated first-pass 
metabolism in the intestine and/or liver [7], V-Gem is stable against cytidine deaminase-
mediated metabolism during in vitro incubations with recombinant enzyme [14]. 
Therefore, V-Gem may protect gemcitabine against metabolism during first-pass transit 
through the intestine and/or liver and undergo subsequent activation. Importantly, V-Gem 
was shown to undergo in vitro activation mediated, at least in part, by the biphenyl 
hydrolase like enzyme [10, 15]. However, while this PEPT1-targeted prodrug V-Gem has 
been evaluated in vitro and shown promising properties for increasing gemcitabine’s oral 
bioavailability (e.g., V-Gem is a PEPT1 substrate, stable against cytidine deaminase-
mediated metabolism, and enzymatically activated), this prodrug’s in vivo pharmacokinetic 
performance has not previously been evaluated. 
 With the ultimate goal of enabling oral gemcitabine administration through 
increasing gemcitabine’s oral bioavailability, along with the knowledge gaps detailed 
above, the following specific aims are proposed: 
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1) To characterize the mechanisms of gemcitabine oral absorption using in situ 
intestinal perfusions in mice 
2) To evaluate the systemic availability and pharmacokinetic performance of 
gemcitabine and the valine gemcitabine prodrug, V-Gem, following oral and 
intravenous administrations in mice  
 5 
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CHAPTER 2  
Background and Literature Review 
 
2.1 Oral Route of Drug Administration 
Oral administration is the most common and preferred route of drug administration 
as it is non-invasive, patient friendly, and cost-effective [1]. Additionally, when compared 
to other common routes of administration (e.g., intravenous, intramuscular, subcutaneous), 
oral administration is associated with higher patient compliance and may offer greater 
flexibility in optimizing the dosing regimen [2]. For most drugs (i.e., systemic-acting 
drugs), however, oral dosing presents additional barriers for drug activity as the active 
pharmaceutical ingredient (API) must be intestinally absorbed (see Section 2.1.1) and avoid 
first-pass metabolism in the gut and liver (see Section 2.1.2) to reach its site of action in 
the body. A drug’s oral bioavailability (Foral) is the fraction of the orally administered dose 
that enters systemic circulation and is a product of the fraction of the administered dose 
that is absorbed from the intestinal lumen (Fa), the fraction escaping first-pass intestinal 
metabolism (Fg), and the fraction escaping first-pass hepatic metabolism (Fh) (Eq. 1).  
 
𝐹𝐹𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜 = 𝐹𝐹𝑜𝑜 𝑥𝑥 𝐹𝐹𝑔𝑔 𝑥𝑥 𝐹𝐹ℎ      (Eq. 1) 
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Low oral bioavailability can preclude oral administration as therapeutic drug levels 
in plasma may be unachievable following oral administration and/or the high inter-
individual variability in drug exposure associated with low bioavailability may be 
unacceptable for the given drug (e.g., drugs with narrow therapeutic indices) [3]. For such 
drugs, either alternative administration routes are utilized or the drug is simply not 
developed as market forces strongly favor the development of orally administrable drugs 
[4].  
2.1.1 Small Intestinal Drug Absorption 
The small intestine is a tubular organ which functions as the main site of absorption 
for orally administered drugs (and nutrients). Although there is high inter- and intrasubject 
variability in the reported macroscopic dimensions of the small intestine, the mean 
diameter is approximately 2 - 4 cm [5] with reported mean lengths ranging from 
approximately 3 m to 7 m [6, 7]. The small intestine is subdivided into the duodenum, 
jejunum, and ileum, which account for approximately 5%, 40%, and 55% of the total 
length, respectively [8]. Although the site of drug absorption in the small intestine is 
dependent on many factors, most drugs are absorbed in the proximal small intestine [9]. 
The inner surface of the small intestine consists of a single-cell thick barrier, the intestinal 
epithelium, which separates the intestinal lumen from the portal blood and regulates the 
uptake of molecules into the body. The epithelium is comprised of intestinal epithelial cells, 
also known as intestinal enterocytes, connected via tight junctions. The surface area of 
contact between the intestinal lumen and epithelium is greatly increased by intestinal 
folding, as well as villi and microvilli structures present on the epithelium. This large 
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surface area, estimated to be ~ 30 m2, aids in the absorption of orally ingested compounds 
[5].  
Movement of drug from the intestinal lumen into portal blood occurs through either 
a paracellular and/or transcellular pathway (Figure 2.1). Paracellular absorption involves 
the movement of drug between intestinal epithelial cells and generally occurs only for small 
hydrophilic molecules with a positive charge [10, 11]. The extent of paracellular absorption 
is greatly limited by the presence of tight junctions between epithelial cells and the small 
surface area of the intestinal epithelium allowing for paracellular uptake of drug from the 
lumen (i.e., < 0.01% of total surface area) [1]. Transcellular absorption is the major route 
of absorption for most drugs and involves the sequential partitioning of drug molecules 
across the epithelial cells’ apical membranes (moving from the intestinal lumen into 
epithelial cells) and basolateral membranes (moving from epithelial cells into the portal 
blood). Drug molecules partition across these membranes mainly by passive diffusion 
through the membrane and/or by carrier-mediated transport [1]. Transcytosis mechanisms 
have also been implicated in the movement of nanocarriers and macromolecules across the 
intestinal membranes [12, 13]. Passive diffusion occurs mainly for lipophilic compounds 
which can travel directly through the lipophilic lipid bilayer comprising the epithelial cell 
membranes, diffusing from higher to lower concentrations. Other compounds, typically 
hydrophilic, are unable to travel directly through the membrane and instead are shuttled 
across the membrane by a transmembrane transport protein (i.e., transporter) [9]. The 
transporters can either be facilitative, allowing only the passive transport of drug down its 
concentration gradient, or active, able to transport drug against the concentration gradient 
[14]. Intestinal enterocytes are known to express many transporters belonging to the 
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adenosine triphosphate-binding cassette (ABC) and solute carrier (SLC) superfamilies on 
both the apical and basolateral membranes. Several of these intestinally expressed 
transporters have been classified by the International Transporter Consortium as having a 
clinically important impact on oral drug absorption and systemic availability [15].  
2.1.2 First-Pass Metabolism 
 While traversing the intestinal epithelium, moving from the intestinal lumen into 
the portal vein, the drug is subject to metabolism by enzymes expressed in intestinal 
epithelial cells [16]. The portal vein then carries the drug to the liver, the main site of 
metabolism in the body, where the drug is subject to metabolism by hepatic enzymes. The 
drug then exits the liver, entering systemic circulation (i.e., hepatic vein). Drug metabolism 
in the intestine and/or liver that occurs prior to the drug entering systemic circulation is 
considered first-pass (presystemic) metabolism and can greatly limit a drug’s oral 
bioavailability. 
2.2 Transporter-Targeted Prodrugs 
Traditionally, passive transcellular diffusion was considered the near exclusive 
mechanism of small molecule drug absorption in the intestine. This view implied that to 
achieve sufficient intestinal absorption an orally administered drug must achieve a 
hydrophilic-lipophilic “sweet spot”: hydrophilic enough to be sufficiently soluble in the 
gastrointestinal tract but lipophilic enough to sufficiently cross the epithelial membranes. 
Guidelines for achieving this “sweet spot” were famously defined by Lipinski et al. [17]. 
However, numerous preclinical and clinical studies have since unequivocally demonstrated 
the importance of transporters in mediating the intestinal absorption and oral bioavailability 
of many drugs [15, 18-20]. Based on this mechanism of absorption, an oral drug 
 11 
development strategy has emerged in which a drug’s intestinal permeability (i.e., the ability 
to move from the intestinal lumen into the intestinal epithelial cells) is increased by 
covalently linking an inactive moiety (IM) to the API, generating a prodrug that is a 
substrate of uptake transporters expressed on the apical membrane of intestinal epithelial 
cells. Following uptake, the prodrug is chemically or enzymatically activated, liberating 
the API (Figure 2.2) [21]. Based on the site of prodrug activation, the prodrug may also 
improve drug stability during first-pass transit through the gut and/or liver, reducing first-
pass metabolism [22]. Thus, transporter-targeted prodrugs can increase a drug’s oral 
bioavailability by increasing intestinal absorption and/or by decreasing first-pass 
metabolism.  
Given market forces favoring the development of orally administrable drugs, many 
compounds with acceptable in vivo activity were/are not developed due to poor predicted 
oral bioavailability. Applying the transporter-targeted prodrug strategy to such compounds 
may improve their oral bioavailability while maintaining their in vivo activity. This 
application will likely become more relevant as toxicity and drug-drug interaction issues 
associated with lipophilic drugs have moved recent drug discovery to a less lipophilic 
space, presumably increasing the prevalence of drugs with poor intestinal absorption [23]. 
Additionally, applying this strategy to drugs currently administered via non-oral routes 
may enable their oral administration [21]. Thus, as more knowledge regarding intestinal 
transporters and prodrug activating enzymes is gained, the potential utilization of this 
technique is vast. 
 
 12 
2.3 Proton-Coupled Oligopeptide Transporters  
The family of proton-coupled oligopeptide transporters (POTs) facilitates the 
uptake of dipeptides, tripeptides, and molecules (including many drugs) which sterically 
and electrostatically resemble peptides (i.e., peptidomimetics). According to the Human 
Genome Organization (HUGO) nomenclature, the human POTs are classified in Family 15 
of the solute carrier group of transmembrane transport proteins (SLC15). The human POTs 
with HUGO designated SLC encoding sequences are peptide transporter 1 (PEPT1, 
SLC15A1), peptide transporter 2 (PEPT2, SLC15A2), peptide/histidine transporter 1 
(PHT1, SLC15A4), and peptide/histidine transporter 2 (PHT2, SLC15A3) [24]. As shown 
in Table 2.1, comparison of amino acid length and sequence identity points to two branches 
in this family: peptide transporters (PEPT1, PEPT2) and peptide/histidine transporters 
(PHT1, PHT2). 
Although PEPT1 and PEPT2 are found in several tissues throughout the body, 
PEPT1 is predominantly expressed on the apical membrane of small intestinal epithelial 
cells and contributes to nutritional absorption while PEPT2 is predominately expressed on 
the apical membrane of renal epithelial cells and contributes to nutritional reabsorption 
[24]. Both transporters generally recognize the same substrates, but PEPT2 typically binds 
substrates with higher affinity. This has led to the designation of PEPT2 as the “high-
affinity, low-capacity” transporter and PEPT1 as the “low-affinity, high-capacity” 
transporter [25]. For instance, the commonly used model dipeptide glycylsarcosine 
(GlySar) is transported by PEPT1 and PEPT2 with Michaelis-Menten constants ranging 
from 500 – 1,500 µM and 50 – 150 µM, respectively [25]. Although this rule holds for 
most substrates (i.e., PEPT2 affinity > PEPT1 affinity), there are some exceptions [26]. 
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Comparatively little is known about PHT1 and PHT2, which are subcellular (i.e., 
endosomal and lysosomal) transporters expressed in tissues throughout the body [24, 27, 
28]. Recent work suggests that PHT1 plays an important role in neural development and 
histamine/histidine homeostasis in the brain [29, 30]. Furthermore, PHT1 has been 
demonstrated to mediate immune response [31, 32] and is believed to be involved in the 
pathogenesis of inflammatory bowel disease [33], lupus [34], and diabetes [35]. Likewise, 
PHT2 is also believed to play a critical role in mediating immune response and has been 
proposed as a therapeutic target for treating inflammatory bowel disease [36, 37]. The 
substrate specificities of PHT1 and PHT2 have not been systematically evaluated but, 
broadly speaking, both transport histidine and the typical POT substrates (i.e., di/tripeptides 
and peptidomimetics) [25]. Recently, efficient cellular models to characterize PHT1 and 
PHT2 transport have been developed and used for preliminary evaluation of substrate 
specificity [38, 39]. 
Interestingly, peptide/peptidomimetic transporters outside of the POT family have 
been reported including human peptide transporter 1 (HPT1) and an opioid peptide 
transporter [40, 41]. Although HPT1 has been shown in vitro to transport peptidomimetics 
including bestatin, cephalexin, and valacyclovir, its in vivo function has not been 
demonstrated [25, 40, 42]. Finally, the Na+-Cl- coupled opioid peptide transporter, which 
shows no transport activity towards non-opioid peptides, is believed to influence the 
distribution of opioid peptides across the blood-brain barrier [41, 43].  
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2.4 Peptide Transporter 1 (PEPT1) 
2.4.1 Localization and Function 
PEPT1 protein expression has been observed in the small intestine, kidney, 
pancreas, bile duct, and monocyte [44-48]. Interestingly, there are conflicting reports 
regarding the expression of PEPT1 in the colon and the potential upregulation of colonic 
PEPT1 expression in inflammatory bowel disease (IBD) [49-52]. Despite expression in 
many tissues, the functional activity of PEPT1 is most prominent in the small intestine and 
kidney. 
PEPT1, which is present on the apical membrane of intestinal enterocytes, serves 
as a “low-affinity, high-capacity” transporter of dipeptides, tripeptides, and 
peptidomimetics from the intestinal lumen into the enterocyte. Utilizing absolute protein 
quantification, Drozdzki et al. quantified the intestinal protein expression of 19 transporters 
in 9 organ donors, showing that PEPT1 accounted for 17%, 31%, 28%, and 2% of total 
transporter expression in the duodenum, jejunum, ileum, and colon, respectively. 
Furthermore, they reported the rank order of absolute intestinal PEPT1 expression as 
jejunum ≈ ileum > duodenum > colon [50]. This is in contrast to the rank order of intestinal 
PEPT1 expression in mice, which was reported as jejunum > duodenum ≈ ileum  > colon 
[53]. The peptides transported by intestinal PEPT1 are typically formed by the digestion of 
dietary and endogenous proteins via peptidases and proteases secreted by the 
stomach/pancreas or bound to the enterocyte’s apical membrane. Once inside the 
enterocyte, most dipeptides and tripeptides are further metabolized into their constituent 
amino acids which are then transported into the portal blood via basolaterally expressed 
amino acid transporters. However, some peptides and peptidomimetics are transported 
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across the basolateral membrane intact [54]. Although a basolateral peptide transporter has 
been shown functionally to exist in intestinal epithelial cells and was recently suggested to 
be the multidrug resistant protein 3 (MRP3) transporter, its identity and many crucial 
transport characteristics remain unknown [55, 56]. Addressing this knowledge gap in drug 
efflux into portal blood may aid in predicting the disposition of orally administered 
peptidomimetic drugs. 
In the kidney, PEPT1 and its “high-affinity, low-capacity” paralog PEPT2 function 
to reabsorb oligopeptides from the glomerular filtrate [57]. Localization studies have 
shown PEPT1 and PEPT2 expression in the proximal and distal regions of the proximal 
tubule, respectively. It is hypothesized that the proximal “low-affinity, high-capacity” 
PEPT1 and distal “high-affinity, low-capacity” PEPT2 work jointly to maximize 
oligopeptide reabsorption [45, 58]. Interestingly, studies in wildtype and PEPT2 knockout 
mice showed PEPT2 accounted for 86% of the renal tubular reabsorption of GlySar [59]. 
The necessity for efficient peptide reabsorption is evidenced by the large contribution of 
peptides to the total circulating amino acid pool. Although this percentage has not been 
reported in human, peptides account for approximately 52%, 65%, and 78% of the total 
circulating amino acid pool in rat, steer, and sheep, respectively [60]. Just as in the intestine, 
the presence of a basolateral peptide transporter in the proximal tubule has been shown 
functionally but its identity and many crucial characteristics are unknown [61]. Given the 
role of glomerular filtrate reabsorption in renal clearance, further study into this topic may 
aid in predicting peptidomimetic drug disposition. More generally, appreciating the wide 
expression profile of PEPT1, further research into its expression/function elsewhere in the 
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body may also improve the prediction of drug disposition and present novel therapeutic 
targets.  
2.4.2 Mechanism of Transport 
In the mid-1980s, Ganapathy and Leibach first suggested peptides are actively 
cotransported with protons in the intestine and kidney [62, 63]. This was later confirmed 
in 1994 as the successful expression of rabbit PEPT1 in Xenopus laevis oocytes allowed 
direct investigation into the mechanism of peptide transport. Using intracellular pH 
monitoring and the two-electrode voltage clamp (TEVC) technique, transport of the 
commonly used model dipeptide GlySar was shown to be electrogenic, H+-coupled, and 
saturable [64]. Utilizing this same technique, it has been demonstrated by many others that 
these conclusions are applicable to PEPT1 substrates regardless of their net charge [65-69]. 
It was thus established that PEPT1-mediated transport is coupled to and powered by the 
movement of protons down an intracellularly-directed proton gradient. The proton gradient 
is established and maintained, at least in part, by the apically expressed Na+/H+ antiporter 
NHE3. NHE3 is driven, in turn, by the intracellularly-directed Na+ gradient established by 
the basolaterally expressed Na+-K+-ATPase [70].  Thus, as illustrated in Figure 2.3, PEPT1 
is a tertiary-active transporter.   
 Given that PEPT1 electrogenically transports peptides regardless of their net 
charge, significant work has explored the stoichiometry of proton and peptide cotransport. 
Using rabbit PEPT1 expressed in Xenopus laevis oocytes, Steel et al. found the 
proton:peptide transport ratio to be 1:1, 2:1, and 1:1 for neutral, acidic, and basic 
dipeptides, respectively [67]. Kottra et al. utilized the same experimental setup and showed 
that peptides carrying a net negative charge at extracellular pH may be transported in their 
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neutral and charged states with high and low affinity, respectively. Similarly, cationic 
dipeptides may be transported in charged and neutral states given positioning of the charge 
on the carboxyl terminal amino acid. They argue that each peptide is directly cotransported 
with only one proton and the transport of a protonated peptide followed by subsequent 
intracellular deprotonation explains the observation that the apparent stoichiometry of 
transport may differ from 1:1 for charged molecules. Thus, they conclude that the observed 
proton:peptide stoichiometry depends on the charged:uncharged ratio of extracellular 
peptides as well as their relative affinities for PEPT1 [66].   
2.4.3 Structure and Pharmacophore  
Ever since PEPT1 was initially cloned in 1994, many techniques have been applied 
to elucidate its structure and key functional domains. On the basis of hydropathy plots, 
PEPT1 was predicted to contain 12 transmembrane domains (TMDs), a large extracellular 
domain (ECD) connecting TMD 9 and 10, and both termini in the cytoplasm as shown in 
Figure 2.4 [64].  Epitope tagging experiments confirmed the number and orientation of the 
TMDs from TMD 4 to the C-terminus. Information regarding the amino-terminal domains 
was not gathered as epitope insertions into this region interfered with PEPT1 translocation 
to the plasma membrane and/or altered transporter function [71]. The crystal structure of 
the ~190 amino acid ECD connecting TMD 9 and 10 was solved by Beale et al. for the 
Mus musculus (i.e., house mouse) PEPT1 homologue, revealing two immunoglobulin 
domains which display a specific interaction with trypsin [72]. Although no complete 
crystal structure has been solved for PEPT1 or a mammalian homologue, crystal structures 
have been solved for several prokaryotic homologues including PEPTSh (Staphylococcus 
hominis), PEPTso (Shewanella oneidensis), PEPTSt (Streptococcus thermophiles), GkPOT 
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(Geobacillus kaustophilus), PEPTSo2 (Shewanella oneidensis), YbgH (Escherichia coli), 
and YePEPT (Yersinia enterocolitica) [73-79]. These crystal structures all reveal a 12 
TMD structure comprised of two six-helical bundles (TMD 1-6 and TMD 7-12) forming a 
‘V’-shaped transporter with two additional TMDs, helix A (HA) and helix B (HB), 
connecting these bundles. HA and HB appear to be absent in metazoan, fungal, and plant 
protein sequences suggesting they are not integral to a conserved transport mechanism [74]. 
Biophysical and molecular modeling simulations have been performed utilizing 
structural knowledge obtained from the PEPTSo and PEPTSt crystal structures. Based on 
these simulations, it was proposed that peptide transport occurs via an alternating access 
mechanism with the periplasmic gate formed by TMD 1, 2, 7, and 8 and the cytoplasmic 
gate formed by TMD 4, 5, 10, and 11 [80]. Importantly, however, these simulations were 
based on crystal structures of prokaryotic PEPT1 homologues which have only a 20 – 30% 
amino acid sequence identity with PEPT1 [72]. Thus, it is possible, although unlikely given 
the evolutionary relationship between bacterial and human transporters, that PEPT1 
transport utilizes a different mechanism.  
Significant work has also gone into elucidating the proton and peptide binding sites 
in PEPT1. First, using site-directed mutagenesis, it has been shown that pH-dependent 
transport and direct proton binding is mediated mainly by H57 on TMD 2 [81]. Much of the 
current information regarding the peptide binding site is the result of co-crystallization of 
PEPT1 bacterial homologues with peptides/peptidomimetics. There are several common 
features in these crystal structures: (1) the peptide binding site is formed by residues from 
TMD 1, 2, 4, 5, 7, 8, 10, and 11; (2) recognition and binding occurs as distinct regions of 
the binding pocket interact with the peptide/peptidomimetic backbone and sidechains; and 
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(3) peptides/peptidomimetics interact with several residues conserved across bacterial and 
mammalian transporters [82, 83]. For example, the peptide binding site in PEPTSo contains 
residues corresponding to the following equivalent residues in PEPT1: R27, Y31, R34, Y64, 
K140, Y167, I170, W294, F297, E595, S599, W622. Lending credibility to these observations, Y167 
, W294, and E595 had been previously implicated in peptide binding to PEPT1 via site-
directed mutagenesis experiments [84]. Furthermore, the recently published crystal 
structure of PEPTSh reports a peptide binding site including, among others, amino acids 
corresponding to Y167 and E595 in PEPT1 [73].  
However, many questions remain regarding PEPT1’s peptide binding site. While 
Samsudin et al., utilized crystal structures of PEPT1 bacterial homologues to generate a 
pharmacophore model, the applicability of this pharmacophore model to PEPT1 is unclear 
given differences in protein sequence/structure [85]. Solving the crystal structure of PEPT1 
or a mammalian homologue would aid in the creation of a more relevant pharmacophore 
model and ultimately aid the discovery and development of peptidomimetic drugs. 
2.4.4 Substrate Specificity 
PEPT1 displays wide substrate specificity as necessitated by its role in the uptake 
of dietary peptides. It is believed that PEPT1 transports most of the 400 dipeptides and 
8,000 tripeptides arising from the 20 naturally occurring amino acids [86]. Furthermore, 
PEPT1 has been shown to transport modified peptides (e.g., N-acetyl-L-phenylalanyl-L-
tyrosine-amide) [87], bacteria-derived peptides (e.g., muramyl dipeptide) [88], and many 
pharmaceutical peptidomimetics (e.g., β-lactam antibiotics, various angiotensin-
converting enzyme inhibitors, bestatin, 5-aminolevulinic acid, valacyclovir, 
valganciclovir) [89-94].   
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Interestingly, PEPT1 substrates do not require a peptide bond but instead a positive 
and negative charge separated by 500 - 630 pm [95]. Brandsch et al. reported that 
compounds carrying a net charge generally have lower PEPT1 affinity, compounds 
containing L-amino-acids generally have higher PEPT1 affinity, and sidechain 
hydrophobicity can influence PEPT1 affinity depending on sidechain location [96]. 
However, Vig et al. presented data showing an important distinction between binding and 
transport as some compounds display high PEPT1 affinity but do not undergo PEPT1-
mediated transport [97]. Although the general trends reported by Brandsch et al. for PEPT1 
binding are similar to those presented by Vig et al. for PEPT1 transport, both studies 
highlight the complexity of thoroughly characterizing PEPT1’s substrate specificity 
without a transporter structure. 
2.4.5 Regulation 
PEPT1 activity is regulated by many factors including biological development, 
exogenous molecules (e.g., diet and drugs), endogenous molecules (e.g., hormones), and 
disease states (e.g., IBD). Regulation of PEPT1 activity occurs largely via mechanisms 
which impact mRNA transcription, mRNA stability, translation of mRNA into PEPT1, 
post-translational PEPT1 modification (e.g., phosphorylation), trafficking of PEPT1 to the 
membrane, and the transmembrane proton gradient which powers PEPT1 transport [24].  
Few studies have been published on the developmental expression, or ontogeny, of 
PEPT1. Shen et. al reported that intestinal PEPT1 expression in rats is induced at birth and 
again during weaning [98]. Mooji et al. completed studies in humans, finding that intestinal 
PEPT1 mRNA expression was approximately 20% lower in neonates/infants (age range: 0 
– 17 weeks) compared to adolescents (age range: 9 – 17 years) (p < 0.05). However, the 
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authors predicted this difference in expression would not lead to clinically relevant 
differences in drug absorption [99].  Alghamdi et al. reported that both the expression and 
localization of renal PEPT1 differ between young, middle-aged, and old rats [100]. 
Dietary consumption has been shown to impact PEPT1 activity as rat PEPT1 
expression levels increase approximately 150 – 200 % following prolonged starvation (4 
days), semistarvation (10 days), or total parenteral nutrition (10 days) [101]. PEPT1 
upregulation was also observed in mice after fasting for as short as 16 hours [102]. 
Additionally, there is a strong positive correlation between dietary protein intake and 
PEPT1 expression in rats while high fat diets have been shown to decrease PEPT1 
expression in mice [103, 104]. Interestingly, diurnal variations in PEPT1 activity have been 
noted in rats and appear to be driven by feeding patterns [105, 106].  
Many drugs have been shown to alter PEPT1 activity both in vitro and in vivo. 
Various phosphodiesterase inhibitors including caffeine, pentoxifylline, and theophylline 
have been shown to the reduce the capacity of PEPT1 transport (Vmax) in Caco-2 cells. It 
is hypothesized that phosphodiesterase inhibitors alter transport by increasing intracellular 
cAMP concentrations, leading to inhibition of the apically expressed NHE3 Na+/H+ 
exchanger and thus reducing the proton gradient which powers PEPT1 transport [107]. 
Alternatively, the α2-adrenergic agonist clonidine, which decreases intracellular cAMP, 
has been shown to increase the capacity of PEPT1 transport in Caco-2 3B cells. Although 
the precise mechanism for this effect is unknown, it may involve increased translocation 
of PEPT1 protein to the plasma membrane [108]. The σ1 receptor agonist pentazocine has 
also been shown to increase the capacity of PEPT1 transport in Caco-2 cells, likely through 
increasing the expression and/or stability of PEPT1 mRNA [109]. It was found that 
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coadministration of the calcium channel blocker nifedipine increased the absorption rate 
of cefixime, a PEPT1 substrate [110]. This observation may be explained by the finding 
that increasing/decreasing intracellular calcium concentrations decreases/increases PEPT1 
mediated transport, likely by altering the activity of NHE3 and thus the proton gradient 
driving PEPT1 transport [111]. The anti-cancer compound 5-fluorouracil (5-FU) was 
shown to increase PEPT1 mRNA and protein expression in rat, an observation the authors 
attributed to “5-FU induced intestinal damage” [112]. Recent work suggests the commonly 
used excipients Solutol HS15, Tween 20, and Tween 80 inhibit PEPT1, although the 
mechanism was not explored [113].  
 There is also extensive hormonal regulation of PEPT1. Insulin and leptin increase 
PEPT1 Vmax by increasing the translocation of preformed PEPT1 to the apical membrane 
while human growth hormone was shown to increase PEPT1 activity by increasing PEPT1 
gene expression [114-116]. Conversely, thyroid hormone was shown to decrease PEPT1 
mRNA levels while epidermal growth factor (EGF) was shown to decrease both mRNA 
and protein levels [117, 118]. However, a subsequent study reported EGF may upregulate 
PEPT1 mRNA expression, and, thus, further investigation is necessary to understand the 
effect of EGF on PEPT1 [119]. The role of hormones in regulating PEPT1 activity in 
certain physiological conditions has been explored, revealing potentially therapeutic roles 
for ghrelin in sepsis and growth hormone in oxidative stress [120, 121].  
 As with other biological processes, disease states may cause or result from aberrant 
PEPT1 activity. Specifically, it has been reported that there is increased colonic PEPT1 
expression in patients with IBD and short bowel syndrome (SBS) [122-124]. Furthermore, 
colonic PEPT1 upregulation in IBD and the potential for IBD to cause colitis-associated 
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cancer (CAC) has led some to propose colonic PEPT1 as a target in treating IBD and 
preventing colitis-associated tumorigenesis [125]. However, in 2014 Wuensch et al. 
presented data suggesting colonic PEPT1 expression actually decreased in humans with 
IBD [126]. Thus, the role of PEPT1 in IBD is unclear and future work addressing this 
pathology could present novel therapeutic targets to address IBD, SBS, and CAC. PEPT1 
has also been shown to be overexpressed in cell lines of various cancers including 
pancreatic, gastric, and prostate [127-129].  
2.4.6 PEPT1-Targeted Prodrugs for Oral Administration 
 The promiscuity and extensive intestinal expression of PEPT1 have made it a 
common target in the development of transporter-targeted prodrugs for oral administration. 
Application of the PEPT1-targeted prodrug technique has been successful in increasing the 
intestinal permeability and oral bioavailability of many drugs both preclinically and 
clinically, with two such prodrugs (valacyclovir and valganciclovir) receiving regulatory 
approval for use in humans [130]. PEPT1-targeted prodrugs are typically generated by 
attaching an amino acid (or dipeptide) to the API through an ester bond [131]. Importantly, 
these prodrugs require in vivo activation to liberate the API and exert a pharmacological 
effect. Thus, a successful PEPT1-targeted prodrug must be a PEPT1 substrate (see section 
2.4.4 for PEPT1 substrate specificity) that also undergoes activation following absorption. 
Accordingly, understanding the in vivo activation of PEPT1-targeted prodrugs is crucial 
for their rational design and development.  
To identify the enzyme(s) responsible for mediating the in vivo activation of 
PEPT1-targeted prodrugs (or a subset of these prodrugs), Kim et al. isolated and identified 
an enzyme from Caco-2 cells that displays significant hydrolytic activity towards 
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valacyclovir and valganciclovir. This enzyme was identified as the serine hydrolase 
biphenyl hydrolase-like protein (BPHL) which shows high RNA expression in human liver 
and kidney and lower expression in intestine, heart, and skeletal muscle [132, 133]. 
Systematic investigation into BPHL substrate specificity revealed that, in addition to 
valacyclovir and valganciclovir, BPHL catalyzes the hydrolytic activation of 3’- and 5’-
amino acid ester prodrugs of several nucleoside analogs including zidovudine, floxuridine, 
benzimidazole, and gemcitabine [134]. In general, BPHL shows a preference for prodrugs 
containing 5’-esters, APIs that function as a labile leaving group, and L-𝛼𝛼-amino acids that 
are small, hydrophobic, and aromatic [134-136]. Furthermore, Asp-123 was shown to be 
crucial in dictating substrate selectivity as it forms a negatively charged area near the active 
site, explaining the preference of BPHL for amino acid prodrugs carrying a free and 
positively charged amino group. This fact, paired with the absence of peptidase activity, 
has led BPHL to be classified as an 𝛼𝛼-amino acid ester hydrolase [136].  
However, work in wildtype and BPHL knockout mice showed conclusively that 
non-BPHL enzymes can also activate valacyclovir in vivo [137]. Subsequent work using 
competitive activity-based protein profiling in Caco-2 cells identified the serine hydrolase 
RBB9 as an activating enzyme of both valacyclovir and the PEPT1-targeted gemcitabine 
prodrug 5’-L-valyl-gemcitabine. The in vivo relevance of RBB9-mediated activation was 
confirmed, showing RBBP9 involvement in the intestinal activation of valacyclovir in mice 
[138]. However, this study was unable to conclude that valacyclovir activation is driven 
solely by BPHL and RBBP9, suggesting that additional enzyme(s) may be involved. 
Identification and characterization of these enzymes may aid in future PEPT1-targeted 
prodrug design and development. Importantly, however, these findings may not be 
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applicable to all PEPT1-targeted prodrugs as the enzymes responsible for mediating 
activation and their relative contributions may vary from prodrug to prodrug.  
2.5 Gemcitabine 
2.5.1 Structure and Physiochemical Properties 
Gemcitabine is a small molecule (molecular weight = 263.2 g/mol) anti-cancer 
compound originally synthesized at Eli Lilly in 1988 [139]. As shown in Figure 2.5A, 
gemcitabine is the fluorine-containing cytidine analogue 2’2’-difluorodeoxycytidine 
(dFdC). Gemcitabine is a hydrophilic (log P = -1.4) weak base (pKa = 3.6) with an aqueous 
solubility of 22 mg/mL (84 mM) [140, 141].  When used clinically, gemcitabine is typically 
supplied as a hydrochloride salt (molecular weight = 299.7 g/mol) which has an aqueous 
solubility of 38 mg/mL (127 mM) [140].  
2.5.2 Clinical Applications in Cancer Therapy 
Gemcitabine received initial FDA approval in 1996 for treatment of locally 
advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) pancreatic 
adenocarcinoma. Gemcitabine has since received FDA approval for additional indications: 
treatment in combination with cisplatin of inoperable and locally advanced (Stage IIIA or 
Stage IIIB) or metastatic (Stage IV) non-small cell lung cancer (1998), treatment in 
combination with paclitaxel of metastatic breast cancer after failure of anthracycline-
containing adjuvant chemotherapy (2004), and treatment in combination with carboplatin 
of advanced ovarian cancer which relapsed at least six months after platinum-based therapy 
(2006) [142]. Additionally, off-label gemcitabine use is quite common as one study found 
that in 2010 approximately 68% of total gemcitabine use was off-label [143]. Table 2.2 
summarizes off-label gemcitabine applications in cancer therapy which received “strong” 
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recommendations for clinical use in the Elsevier Gold Standard's Clinical Pharmacology 
compendium [144]. Furthermore, gemcitabine therapy is often combined with radiation as 
gemcitabine acts as a radiosensitizer [145]. Depending upon the indication and the use of 
combination therapies (i.e., coadministered medications), a typical gemcitabine regimen 
involves weekly administration of 1000 mg/m2 – 1250 mg/m2 over 21- or 28-day cycles 
via a 30-minute constant-rate intravenous (IV) infusion [142]. When used in combination 
with radiation therapy, gemcitabine may be administered at much lower doses [146-149]. 
Interestingly, there are clinical data showing that increasing the length of the 
infusion, while administering an equal or even lower total gemcitabine dose, can increase 
cellular exposure to the active gemcitabine metabolite, gemcitabine triphosphate (dFdCTP) 
[150, 151]. However, the clinical relevance of this is unclear as studies comparing clinical 
outcomes between standard 30-minute gemcitabine infusions and prolonged infusions 
present conflicting results [152]. For instance, a Phase II study in patients with pancreatic 
adenocarcinoma showed that a prolonged gemcitabine infusion performed better than a 
standard gemcitabine infusion in both 1-year survival (28.8% vs. 9%, p = 0.014) and 2-
year (18.3% vs. 2.2%, p = 0.007) survival [151]. However, a Phase III trial in patients with 
pancreatic adenocarcinoma reported that prolonged infusions did not improve survival, 
relative to standard infusions [153]. Such discrepancies are not uncommon in the literature 
and may be due to differences in the patient population, the dosing regimens studied, the 
clinical endpoints, or a combination of these factors. Furthermore, although recent meta-
analysis suggest that prolonging gemcitabine infusion may increase the overall response 
rate when treating non-small cell lung cancer and increase median survival when treating 
pancreatic adenocarcinoma, more large scale clinical trials are required to both prove the 
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clinical utility of prolonged gemcitabine infusions and optimize such dosing regimens (e.g., 
dose, length of infusion, frequency of administration) [154, 155]. Thus, gemcitabine is still 
most frequently administered weekly as a 30-minute infusion [156].  
Interestingly, although gemcitabine was first approved over 20 years ago, according 
to ClinicalTrials.gov (as of May 19, 2020) there are currently 73 “not yet recruiting” , 387 
“recruiting” , and 207 “active” clinical trials examining gemcitabine in treating a range of 
cancers [157]. Thus, gemcitabine remains commonly used in the clinic and, as evidenced 
by the number of trials involving gemcitabine currently planned and in progress, it appears 
gemcitabine will remain an integral component of cancer therapy.  
2.5.3 Clinical Pharmacokinetics 
Absorption/Administration 
Gemcitabine has an oral bioavailability of approximately 10% and is thus 
administered as a zero-order intravenous infusion over a 30 minute period [142, 158]. 
Gemcitabine plasma concentrations typically plateau 15 - 30 minutes into an infusion, with 
average maximum plasma concentrations (Cmax) (i.e., concentrations at the end of the 
infusion) ranging from 30 - 37 µM following a 1000 mg/m2 dose and 50 - 70 µM following 
a 1250 mg/m2 dose [159, 160].  
Distribution  
A two-compartment population pharmacokinetic (POPPK) model of gemcitabine 
was developed using data collected from seven studies (353 patients total). This model 
revealed that gemcitabine’s steady-state volume of distribution (Vdss) is approximately 65 
L/m2 when administered via a “short” infusion (i.e., < 70 minutes) and approximately 385 
L/m2 when administered via a “long” infusion (i.e., > 70 minutes). The central compartment 
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volume (V1) is 12.2 and 17.5 L/m2 for women and men, respectively, following both 
“short” and “long” infusions. The peripheral compartment volume (V2) does not show a 
gender-dependency and is 47.4 L/m2 following “short” infusions and 370 L/m2 following 
“long” infusions [161]. However, the clinical impact of the increased distribution seen with 
longer infusion times is unclear (see Section 2.5.2). The major metabolite of gemcitabine, 
2’,2’-difluorodeoxyuridine (dFdU, Figure 2.5B), has been described using both a 2- and 3-
compartment model [162, 163].  
The distribution/cellular uptake of gemcitabine and dFdU is mediated by two solute 
carrier (SLC) transporter families: the SLC28 family of concentrative nucleoside 
transporters (CNTs), which are sodium-dependent and unidirectional transporters able to 
transport substrates against their concentration gradient (i.e., from low to high 
concentrations), and the SLC29 family of equilibrative nucleoside transporters (ENTs), 
which are sodium-independent and bidirectional transporters that facilitate substrate 
movement down their concentration gradient (i.e., from high to low concentrations) [164, 
165]. Within these families, gemcitabine is a substrate of four transporters localized to the 
plasma membrane: CNT1 (Km = 24 µM), CNT3 (Km = 60 µM), ENT1 (Km = 160 µM), and 
ENT2 (Km =740 µM) [166, 167]. It is believed that ENT1 is mainly responsible for 
gemcitabine distribution and a recent meta-analysis of clinical data concluded that high 
ENT1 protein expression in pancreatic tumors is associated with increased overall survival 
in patients receiving gemcitabine treatment [164, 168]. A similar positive correlation 
between tumoral ENT1 expression and gemcitabine response was observed in patients with 
bladder and biliary tract cancer [169, 170]. Finally, the stark difference in Vdss seen 
following short and long infusions may be due, in small part, to saturation of uptake 
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transporters (e.g., CNT1, CNT3) at the high plasma gemcitabine concentrations generated 
during short infusions [166, 167].  
Metabolism and Excretion  
 The same gemcitabine POPPK model described above reported that gemcitabine 
clearance is gender-dependent (i.e., approximately 40% higher in men than women) and 
age-dependent (i.e., decreases approximately 55% from age 29 – 79) as shown in Table 
2.3. Although no specifics were provided, the authors state that clearance is comparable 
following “short” and “long” infusions [161]. When administered as a standard 30-minute 
infusion, clearance is independent of dose from 40 – 3650 mg/m2 but may show dose-
dependency above 3650 mg/m2 [171, 172].  
Gemcitabine elimination is largely driven by cytidine deaminase (CDA)-mediated 
metabolism into dFdU, occurring mainly in the liver. Based on the results of an intravenous 
radiolabeled pharmacokinetic study in 5 patients, CDA-mediated metabolism accounts for 
over 90% of gemcitabine clearance while renal excretion of intact gemcitabine accounts 
for less than 10% [142].  This result is consistent with subsequent gemcitabine PK studies 
[171, 172]. According to the package insert, gemcitabine’s plasma half-life (t1/2) ranges 
from 42 - 94 minutes following a “short” infusion [142].  Interestingly, there is large 
variation in published t1/2 values following “short” infusions as Peters et al. reported 
gemcitabine’s t1/2 ranges from 5 - 20 minutes in a widely cited 2007 paper [172]. This 
discrepancy may arise from difficulties in separating the distribution t1/2 (t1/2,𝝰𝝰) and the 
elimination t1/2 (t1/2,β), as a 2015 paper reported t1/2,𝝰𝝰 values of approximately 10 minutes 
and t1/2,β values of approximately 60 minutes [173]. Thus, it is possible that Peters et al. 
reported t1/2,𝝰𝝰 while the true t1/2,β is longer, as reported in the package insert. Regardless of 
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these discrepancies, gemcitabine’s short t1/2 prevents gemcitabine accumulation during 
weekly administration [174]. When administered via a “long” infusion, gemcitabine’s t1/2 
increases to 295 - 638 minutes, reflecting an increased Vdss [161].  
 The main gemcitabine metabolite, dFdU, is eliminated unchanged in urine with a 
mean t1/2 ranging from 33 – 84 hr [175]. Although dFdU is present at concentrations 
ranging from 1 - 6 µM one week after administration of a standard gemcitabine dose, there 
is no measurable dFdU accumulation with weekly gemcitabine administration [174]. While 
some believe dFdU may contribute to gemcitabine’s cytotoxic and radiosensitizing effects 
in vivo [176-178], recent work reported very low concentrations of phosphorylated dFdU 
nucleotides (much lower than gemcitabine nucleotides) in peripheral blood mononuclear 
cell samples collected from patients receiving gemcitabine therapy [179]. This finding, 
paired with the higher potency of gemcitabine relative to dFdU as both a cytotoxic and 
radiosensitizing agent [178-180], suggests that dFdU activity may not be clinically 
relevant, as hypothesized by others (D. Shewach, personal communication, July 29, 2020).  
2.5.4 Mechanism of Action 
Intracellular Generation and Accumulation of Active Gemcitabine Metabolites 
 Within one week of radiolabeled gemcitabine intravenous administration, nearly all 
(92 – 98%) of the administered dose is recovered in urine as gemcitabine and dFdU [142]. 
However, additional gemcitabine metabolites are generated intracellularly in vivo as 
illustrated in Figure 2.6. Although these additional metabolites are not found at quantifiable 
levels in plasma or urine, they drive gemcitabine’s pharmacological action. The primary 
active form of gemcitabine, gemcitabine triphosphate (dFdCTP), is generated 
intracellularly by three sequential phosphorylation events: (1) deoxycytidine kinase (dCK)-
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mediated phosphorylation of gemcitabine, forming gemcitabine monophosphate 
(dFdCMP); (2) pyrimidine nucleoside monophosphate kinase (UMP-CMP kinase)-
mediated phosphorylation of dFdCMP, forming gemcitabine diphosphate (dFdCDP); and 
(3) undetermined enzyme (potentially nucleoside diphosphate kinase)-mediated 
phosphorylation of dFdCDP forming gemcitabine triphosphate (dFdCTP). Metabolic 
inactivation processes are also occurring simultaneously, including CDA-mediated 
deamination of gemcitabine, 5’-nucleotidase (5’-NT)-mediated dephosphorylation of 
dFdCMP, and deoxycytidylate deaminase (dCTD)-mediated deamination of dFdCMP 
[181]. Furthermore, dFdU is phosphorylated forming dFdU monophosphate (dFdUMP), 
dFdU diphosphate (dFdUDP), and dFdU triphosphate (dFdUTP) [177, 179].  
dCK-mediated gemcitabine phosphorylation is the rate limiting step of dFdCTP 
formation and a positive correlation between dCK expression in pancreatic cancer tissues 
and overall survival following gemcitabine treatment has been demonstrated [182, 183]. 
dCK phosphorylates gemcitabine with a Km ranging from roughly 1 - 10 µM, depending 
on the source of the phosphate donor (e.g., ATP, UTP, NTP mixture) [184, 185]. Clinical 
trial results support the relevance of dCK saturation as intracellular dFdCTP accumulation 
plateaus above gemcitabine plasma concentrations of 15 - 20 µM [171, 186]. Importantly, 
such saturating concentrations are reached following 30 minute gemcitabine infusions at 
1,000 mg/m2 (Cmax = 30-37 µM) or 1,250 mg/m2 (Cmax = 50 - 70 µM) [159, 160].  
Increasing the length of the gemcitabine infusion would increase exposure to plasma 
gemcitabine concentrations of ≤ 15 – 20 µM, theoretically leading to increased intracellular 
dFdCTP accumulation [187]. As described in Section 2.6.2, longer infusion times have in 
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fact been shown in various clinical trials to increase intracellular dFdCTP accumulation, 
but the clinical relevance of this is unclear.  
In various cancer cell lines, the removal of intracellular gemcitabine and 
gemcitabine metabolites was shown to occur mainly through the efflux of gemcitabine via 
SLC transporters (likely ENT1) and the efflux of dFdU via members of the ATP-binding 
cassette transporter subfamily C (ABCC) [177, 188]. Interestingly, the cellular retention of 
dFdCTP is quite long in comparison to other tri-phosphate nucleoside analogs (e.g., Ara-
C), which may be important for gemcitabine’s cytotoxicity. For instance, in Chinese 
hamster ovary (CHO) cells, Ara-c triphosphate elimination is linear (t1/2 = 0.7 hr), while 
dFdCTP elimination is linear at low concentrations (t1/2 = 3.9 hr) and biphasic at high 
concentrations, (t1/2 𝛼𝛼 = 3.9 hr, t1/2 β > 16 hr) [189]. Biphasic dFdCTP elimination was also 
seen in leukemic cells with t1/2 𝛼𝛼 values ranging from 0.6 – 1.3 hr and t1/2 β values ranging 
from 5 – 43 hr, depending on dFdCTP concentration [176]. While t1/2 values were not 
reported, dFdCTP was also shown to be well retained in several solid tumor cell lines. For 
instance, in the A2780 ovarian cancer cell line, high levels of dFdCTP remained 24 hours 
after removal of gemcitabine from the incubation medium (>70% of concentration seen 
when gemcitabine was first removed from the incubation) [190]. The long cellular retention 
and concentration-dependent biphasic elimination of dFdCTP is believed to result from the 
inhibition of various intracellular enzymes by gemcitabine metabolites, which ultimately 
increases the formation of dFdCTP and decreases the formation of the cellular efflux 
substrates dFdU and gemcitabine. This mechanism, known as self-potentiation, will be 
thoroughly discussed in the following subsection [176, 191].  
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Cytotoxic Mechanism of Action 
There are many proposed mechanisms through which gemcitabine exerts its 
cytotoxic effect. The main mechanism involves dFdCTP incorporation into DNA in place 
of deoxycytidine triphosphate (dCTP), blocking cell cycle progression at the G1/S-phase 
boundary [192]. In a cell free system (i.e., a system containing DNA polymerase but 
lacking the repair enzymes found in intact cells), it was demonstrated that incorporation of 
dFdCTP is followed by the incorporation of one additional nucleotide, at which point chain 
elongation is terminated. The penultimate positioning of dFdCMP prevents both DNA 
polymerase mediated chain elongation and the removal of dFdCMP via 3’5’ 
exonucleases [192]. While the relevance of this process, known as “masked-chain 
termination”, is not known for intact cancer cells, dFdCTP incorporation into DNA has 
been shown to be essential for gemcitabine-induced apoptosis [193]. Several intracellular 
signaling pathways have been implicated in mediating gemcitabine-induced apoptosis 
including the caspase, p38 mitogen-activated protein kinase (MAPK), p53, NF-κβ, ERK, 
and Akt pathways [194-199]. It has also been shown that dFdCTP incorporation can lead 
to topoisomerase I poisoning, causing accumulation of strand breaks and cell death [200]. 
Interestingly, dFdUTP is also incorporated into DNA and both dFdCTP and dFdUTP are 
incorporated into RNA [177]. While some hypothesize that dFdUTP is an active metabolite 
[201], it is likely that dFdUTP incorporation into DNA and RNA is not clinically relevant, 
as described in Section 2.3.  
The incorporation of dFdCTP into DNA, and subsequent cytotoxic effect, is 
enhanced by gemcitabine metabolites via a process known as self-potentiation. As shown 
in Figure 2.7, dFdCDP and dFdCTP increase cytotoxicity by depleting deoxycytidine 
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triphosphate (dCTP) pools and increasing the intracellular formation of dFdCTP, 
respectively, thereby increasing the likelihood of dFdCTP incorporation into DNA. First, 
dFdCDP irreversibly inhibits ribonucleotide reductase (RR), the enzyme responsible for 
conversion of nucleoside diphosphates (NDP) to deoxynucleoside diphosphates (dNDP), 
ultimately depleting deoxynucleoside triphosphate (dNTP) pools [202, 203]. Interestingly, 
while gemcitabine-mediated RR inhibition primarily depleted dCTP levels in the leukemia 
cell line K562, gemcitabine-mediated RR inhibition primarily depleted dATP levels in 
many solid tumor cell lines (e.g., U251, D54, HT-29) [202, 204, 205]. dFdCTP directly 
inhibits dCTD, decreasing dFdCMP inactivation and increasing dFdCTP formation. These 
self-potentiating mechanisms are hypothesized to be responsible for the long cellular 
retention time and biphasic elimination of dFdCTP, as previously mentioned [176]. 
Furthermore, dFdUMP-mediated inhibition of thymidylate synthase may alter cellular 
deoxythymidine triphosphate (dTTP) pools, increasing nucleotide mis-incorporation and 
DNA damage [206]. Further clarification of the mechanisms underlying gemcitabine 
cytotoxicity and sensitivity/resistance will enable better predictions of patient efficacy and 
the rational design of combination therapies addressing multiple pathways. 
Radiosensitizing Mechanism of Action 
Gemcitabine is a potent radiosensitizer both in vivo and in vitro. Clinically, 
combining radiation therapy with low dose gemcitabine (often at a fraction of the standard 
chemotherapy dose) has shown promising results in treating various solid tumor cancers, 
including pancreatic bladder, head and neck, and malignant gliomas [148, 149, 207, 208]. 
However, toxicity concerns may severally limit the administrable gemcitabine dose when 
treating certain tumor types, especially when extended nodal irradiation is performed [209]. 
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Interestingly, however, one study showed that full dose gemcitabine (1000 mg/m2) and 
cisplatin (40 mg/m2) can be safely combined with conformal radiation therapy in treating 
pancreatic cancer [210]. In vitro, gemcitabine was shown to induce radiosensitization in 
HT-29 cells at 10 nM. This effect increased with concentration until 1.0 µM, above which 
a plateau in radiosensitization is observed [204]. The radiosensitizing effect of gemcitabine 
was further explored in colon carcinoma cells and these results suggest that dFdCDP-
mediated inhibition of ribonucleotide reductase and the resulting depletion and imbalance 
of deoxynucleotides, especially deoxyadenosine triphosphate (dATP), is an important 
factor in radiosensitization [204]. Experiments in two pancreatic cancer cell lines reported 
a similar conclusion [211]. The nucleotide imbalance leads to increased nucleotide mis-
incorporation and radiosensitization if the mismatches are not repaired prior to irradiation. 
Thus, cells with decreased mismatched repair activity show greater gemcitabine induced 
radiosensitization [212]. On the other hand, homologous recombination repair was shown 
to be required for gemcitabine induced radiosensitization [213]. It was proposed that 
following drug washout and irradiation, major DNA damage is repaired (i.e. double strand 
breaks via homologous recombination) at the expense of repairing mismatches, leading to 
greater DNA damage than observed with radiation or gemcitabine treatment alone. 
Interestingly, upregulated homologous recombination repair (HRR) activity has been 
found in many cancer types and the extent of HRR activity may be an important factor in 
gemcitabine radiosensitization [214]. Finally, there are preliminary results suggesting that 
the radiosensitization effect of gemcitabine is increased by performing longer infusions, 
likely due to increased intracellular dFdCDP accumulation [215]. Again, however, 
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additional large-scale clinical studies will be needed to explore the relationship between 
infusion time and radiosensitization.  
2.6 PEPT1-Targeted Gemcitabine Prodrugs for Oral Administration 
Gemcitabine has a low oral bioavailability of approximately 10%, due, in part, to 
extensive first-pass metabolism by CDA [158].  Additionally, many studies assume that 
gemcitabine has low intestinal permeability, implying that oral bioavailability is further 
limited by incomplete intestinal absorption [216-219]. Gemcitabine’s low oral 
bioavailability, paired with its narrow therapeutic index, precludes oral administration 
[220]. However, oral gemcitabine administration is preferable to IV administration as oral 
administration is more patient-friendly, reduces the cost and complexity of administration, 
and would enable dosing regimens that are hypothesized to improve gemcitabine efficacy 
(e.g., dosing which mimics a prolonged infusion and metronomic dosing) [1, 154, 221]. To 
this end, PEPT1-targeted amino acid/dipeptide ester gemcitabine prodrugs have been 
developed and evaluated in vitro and in situ, showing promise in enabling oral 
administration. These prodrugs, 5’-L-valyl-gemcitabine (L-Val-Gem), 5’-D-valyl-
gemcitabine (D-Val-Gem), 5’-L-phenylalanyl-gemcitabine (L-Phe-Gem), 5’-D-
phenylalanyl-gemcitabine (D-Phe-Gem), and 5’-L-Phenylalanyl-L-tyrosyl-gemcitabine (L-
Phe-L-Tyr-Gem), are shown in Figure 2.8.  
Such prodrugs have been shown to address the two factors believed to limit 
gemcitabine oral bioavailability: (1) low intestinal permeability and (2) extensive first-pass 
metabolism. First, as shown in Table 2.4, all tested prodrugs displayed a higher apparent 
permeability (Papp) than gemcitabine when incubated at 100 µM with Caco-2 cell 
monolayers [218, 222]. Although the Papp of L-Phe-L-Tyr-Gem was not determined, L-
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Phe-L-Tyr-Gem uptake was greater than gemcitabine uptake when incubated at 100 µM in 
Caco-2 cells. Interestingly, the Caco-2 uptake of all prodrugs, except L-Phe-L-Tyr-Gem, 
was statistically significantly reduced in the presence of a competitive PEPT1 inhibitor (10 
mM glycyl-proline). This suggests that the increased uptake of L-Phe-L-Try-Gem, relative 
to gemcitabine, is not due to PEPT1-mediated transport [222]. Likewise, in situ jejunal 
perfusions in mice revealed increased effective intestinal permeability (Peff) for all 
prodrugs, relative to gemcitabine, when perfused at 100 µM. The Peff  values for 
gemcitabine and the prodrugs reported in the literature by Tsume el al. contain a unit error 
[218, 222]. Interestingly, approximately 30% of the perfused gemcitabine was found in 
perfusion outlet samples as cytosine, signifying extensive glycosidic bond breakage 
(Tsume laboratory notebook). While this metabolic pathway has been reported for other 
nucleoside analogs, including floxuridine, it has not been reported for gemcitabine [223]. 
Next, as seen in Table 2.5, in vitro incubations of gemcitabine and gemcitabine prodrugs 
at 200 µM with purified CDA enzyme at 5.0 ng/µL showed that all prodrugs had increased 
resistance to CDA-mediated deamination, relative to gemcitabine [224]. Finally, following 
a 2 hr in situ jejunal perfusion of gemcitabine and the gemcitabine prodrugs at 100 µM, the 
plasma concentrations of prodrug (following prodrug perfusion), gemcitabine, and 
cytosine were determined. These results, presented in Figure 2.9, show a general trend that 
total drug concentrations in plasma are higher following prodrug perfusion and that four of 
the five prodrugs are found in systemic circulation intact. Importantly, while the prodrugs 
show promise for increasing gemcitabine oral bioavailability based on both in vitro and in 
situ experiments, their in vivo pharmacokinetic performance has not yet been evaluated.  
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Tables and Figures 
 
 
Table 2.1 Amino acid length and sequence identity of the human proton-coupled 
oligopeptide transporters  
 
 
 
 
 
 
Sequence identities were calculated using the Basic Local Alignment Search Tool 
(BLAST) provided by the National Center for Biotechnology Information [225].  PEPT1, 
peptide transporter 1; PEPT2, peptide transporter 2; PHT1, peptide/histidine transporter 1; 
PHT2, peptide/histidine transporter 2. 
  
Transporter Amino Acid Length 
Sequence 
Identity 
with PEPT1 
Sequence 
Identity with 
PEPT2 
Sequence 
Identity 
with PHT1 
Sequence 
Identity 
with PHT2 
PEPT1 708 - 49.2% 23.1% 23.8% 
PEPT2 729 49.2% - 25.8% 24.2% 
PHT1 577 23.1% 25.8% - 50.6% 
PHT2 581 23.8% 24.2% 50.6% - 
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Table 2.2 Off-label uses of gemcitabine receiving a “Strong” recommendation for use from 
Elsevier Gold Standard’s Clinical Pharmacology compendium  
 
Indication Coadministered Medication 
Biliary tract cancer (advanced or metastatic) cisplatin 
Non-Hodgkin lymphoma (aggressive, in transplant 
eligible patients with relapsed or refractory cases) 
cisplatin + dexamethasone + 
rituximab (for CD20-positive) 
Non-small cell lung cancer (advanced or 
metastatic) paclitaxel 
Non-small cell lung cancer (unresectable, locally 
advanced or metastatic) 
carboplatin 
docetaxel 
Pancreatic cancer (adjuvant treatment) none 
Pancreatic cancer (advanced) nab-paclitaxel 
Pancreatic ductal adenocarcinoma (adjuvant 
treatment) capecitabine 
Translational-cell bladder cancer (locally 
advanced or metastatic) cisplatin 
 
Data aggregated from [144].  
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Table 2.3 Age- and gender-dependent population estimates of gemcitabine clearance  
 
 
 
 
 
 
 
 
Clearance presented as L/hr/m2. Parameters from [161].   
  
Age Male Female 
29 92.2 66.0 
45 75.7 54.2 
56 55.1 39.5 
79 40.7 29.2 
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Table 2.4 Permeability of gemcitabine and gemcitabine prodrugs determined in vitro in 
Caco-2 cells and in situ via jejunal perfusions in mice 
 
Drug or Prodrug Papp, Caco-2 (x 10-6 cm/s) 
Peff, jejunal mouse perfusion              
(x 10-5 cm/s) 
Gemcitabine 1.0 ± 0.2 0.2 ± 0.02 
L-Val-Gem 4.0 ± 0.1 * 3.6 ± 0.9 * 
D-Val-Gem 3.9 ± 0.1 * 1.9 ± 0.6 * 
L-Phe-Gem 3.8 ± 0.9 * 3.4 ± 0.3 * 
D-Phe-Gem 4.5 ± 0.9 * 2.2 ± 0.4 * 
L-Phe-L-Tyr-Gem NA 2.2 ± 0.4 * 
 
Data obtained from Dr. Yasuhiro Tsume’s notebook. Caco-2 incubations and jejunal 
perfusions both done with test compounds at 100 µM.  Data reported as mean ± SD (n = 
3). *p < 0.05, compared to gemcitabine. Papp, apparent permeability; Peff, effective 
permeability; L-Val-Gem, 5’-L-valyl-gemcitabine; D-Val-Gem, 5’-D-valyl-gemcitabine; 
L-Phe-Gem, 5’-L-phenylalanyl-gemcitabine; D-Phe-Gem, 5’-D-phenylalanyl-gemcitabine; 
L-Phe-L-Tyr-Gem, 5’-L-phenylalanyl-L-tyrosyl-gemcitabine.  
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Table 2.5 Half-life of gemcitabine and gemcitabine prodrugs when incubated with cytidine 
deaminase 
 
 
 
 
 
 
 
 
 
 
 
Data from [224]. Incubations contained tested compounds at 200 µM and recombinant 
cytidine deaminase at 5.0 ng/µL. t1/2, half-life; L-Val-Gem, 5’-L-valyl-gemcitabine; D-Val-
Gem, 5’-D-valyl-gemcitabine; L-Phe-Gem, 5’-L-phenylalanyl-gemcitabine; D-Phe-Gem, 
5’-D-phenylalanyl-gemcitabine; L-Phe-L-Tyr-Gem, 5’-L-phenylalanyl-L-tyrosyl-
gemcitabine. 
  
Drug or Prodrug t1/2 (min) 
Gemcitabine <3 
L-Val-Gem >120 
D-Val-Gem >120 
L-Phe-Gem 44.6 ± 18.8 
D-Phe-Gem >120 
L-Phe-L-Tyr-Gem >120 
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Figure 2.1 The (a) paracellular and (b) transcellular pathways of intestinal drug absorption.  
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Figure 2.2 Application of the transporter-targeted prodrug strategy to increase a drug’s 
oral bioavailability. Dashed and solid lines represent passive diffusion and transporter 
mediated partitioning across epithelial membranes, respectively. (1) The active 
pharmaceutical ingredient (API) is unable to efficiently diffuse through apical membrane. 
(2) The API is covalently bound to an inactive moiety (IM), generating a prodrug that 
undergoes transporter mediated uptake into the enterocyte. (3) Intestinal metabolism of 
prodrug releases the API and the API crosses the basolateral membrane through either 
passive diffusion or transporter mediated efflux. (4) The prodrug crosses the basolateral 
membrane through either passive diffusion or transporter mediated efflux. 
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Figure 2.3 Schematic representation of the transporters (represented by large circles) 
involved in the PEPT1-mediated intestinal uptake of peptides/peptidomimetics. The 
basolaterally expressed Na+-K+-ATPase generates an intracellularly-directed Na+ gradient. 
The apically expressed Na+/H+ antiporter (NHE3) utilizes this Na+ gradient to generate an 
intracellularly-directed H+ gradient. The apically expressed peptide transporter 1 (PEPT1) 
utilizes this gradient to cotransport a proton and peptide/peptidomimetic into the 
enterocyte.  
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Figure 2.4 Membrane topology of PEPT1 (figure adapted from [226]).  
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Figure 2.5 Structures of (a) gemcitabine and (b) the deaminated gemcitabine metabolite 
dFdU. 
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Figure 2.6 Schematic of intracellular gemcitabine activation with the enzyme mediating 
each step presented in italics. dFdU, 2’,2’-difluorodeoxyuridine; CDA, cytidine 
deaminase; dCK, deoxycytidine kinase; 5’-NT, 5’-nucleotidase; dCTD, deoxycytidylate 
deaminase; UMP-CMP kinase, pyrimidine nucleoside monophosphate kinase. Figure 
adapted from [179].  
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Figure 2.7 Schematic of gemcitabine self-potentiation with metabolite activity shown as 
a dotted arrow. dFdU, 2’,2’-difluorodeoxyuridine; CDA, cytidine deaminase; dCK, 
deoxycytidine kinase; 5’-NT, 5’-nucleotidase; dCTD, deoxycytidylate deaminase; UMP-
CMP kinase, pyrimidine nucleoside monophosphate kinase; RR, ribonucleotide 
reductase; NDP, nucleoside diphosphate; dNDP, deoxynucleoside diphosphate; [dNTP], 
intracellular concentration of deoxynucleoside triphosphates; TS, thymidylate synthase; 
dUMP, deoxyuridine monophosphate; dTMP deoxythymidine monophosphate. Figure 
adapted from [179].  
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Figure 2.8 Structures of previously synthesized PEPT1-targeted amino acid and 
dipeptide ester gemcitabine prodrugs from the Dr. Gordon Amidon Laboratory [222, 227] 
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Figure 2.9 The concentrations of prodrug, gemcitabine, and cytosine in mouse plasma 
following a 2 hr in situ jejunal perfusion of gemcitabine and the gemcitabine prodrugs at 
100 µM. *p<0.05, total drug concentration compared to gemcitabine. Amino acid ester 
prodrug (left panel) data taken from [218] and dipeptide ester prodrug data (right panel) 
taken from [222]. L-Phe-Gem, 5’-L-phenylalanyl-gemcitabine; D-Phe-Gem, 5’-D-
phenylalanyl-gemcitabine; L-Val-Gem, 5’-L-valyl-gemcitabine; D-Val-Gem, 5’-D-valyl-
gemcitabine; L-Phe-L-Tyr-Gem, 5’-L-phenylalanyl-L-tyrosyl-gemcitabine. 
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CHAPTER 3  
Mechanisms of Gemcitabine Oral Absorption as determined by In Situ Intestinal 
Perfusions in Mice 
3.1 Abstract 
Gemcitabine is a widely used chemotherapeutic drug that is administered via intravenous 
infusion due to a low oral bioavailability of only 10%. This low oral bioavailability is 
believed to be the result of gemcitabine’s low intestinal permeability and oral absorption, 
followed by significant presystemic metabolism. In the present study, we sought to define 
the mechanisms of gemcitabine intestinal permeability, the potential for saturation of 
intestinal uptake, and the transporter(s) responsible for mediating the oral absorption of 
drug using in situ single-pass intestinal perfusions in mice. Concentration-dependent 
studies were performed for gemcitabine over 0.5 to 2000 µM, along with studies of 5 µM 
gemcitabine in a sodium-containing buffer ± thymidine (which can inhibit concentrative 
(i.e., CNT1 and CNT3) and equilibrative (i.e., ENT1 and ENT2) nucleoside transporters) 
or dilazep (which can inhibit ENT1 and ENT2), or in a sodium-free buffer (which can 
inhibit CNT1 and CNT3). Our findings demonstrated that gemcitabine was, in fact, a high-
permeability drug in the intestine at low concentrations, that jejunal uptake of gemcitabine 
was saturable and mediated almost exclusively by nucleoside transporters, and that jejunal 
flux was mediated by both high-affinity, low-capacity (Km = 27.4 µM, Vmax = 3.6 
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pmol/cm2/s) and low-affinity, high-capacity (Km = 700 µM, Vmax = 35.9 pmol/cm2/s) 
transport systems. Thus, CNTs and ENTs at the apical membrane allow for gemcitabine 
uptake from the lumen to enterocyte, whereas ENTs at the basolateral membrane allow for 
gemcitabine efflux from the enterocyte to portal venous blood.  
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3.2 Introduction 
 Gemcitabine (2′,2′-difluoro-2′-deoxycytidine; dFdC) is a pyrimidine nucleoside 
analogue used in the treatment of various solid tumors [1-4]. Gemcitabine distribution and 
cellular uptake is mediated by the action of two evolutionarily unrelated transmembrane 
transporter families: the concentrative nucleoside transporters (CNTs) and the equilibrative 
nucleoside transporters (ENTs), belonging to the solute carrier (SLC) families 28 and 29, 
respectively [5, 6]. Specifically, gemcitabine is a substrate of the pyrimidine selective 
transporter CNT1 and the broadly selective purine and pyrimidine transporters CNT3, 
ENT1, and ENT2 [7, 8]. CNT1 and CNT3 function as concentrative and unidirectional 
sodium:substrate cotransporters, whereas ENT1 and ENT2 function as equilibrative and 
bidirectional sodium-independent transporters [9]. It has also been demonstrated that 
CNT3 can function as a proton:substrate cotransporter, albeit with altered transport activity 
and substrate specificity [10].   
 Following cellular uptake, gemcitabine undergoes phosphorylation events forming 
the active metabolites gemcitabine diphosphate (dFdCDP) and triphosphate (dFdCTP) 
[11]. dFdCTP is incorporated into DNA in place of the natural substrate deoxycytidine 
triphosphate, preventing chain elongation [12] and leading to apoptosis [13]. dFdCDP 
inhibits ribonucleotide reductase, depleting the pool of deoxynucleotide triphosphates and 
increasing dFdCTP incorporation into DNA [14]. Additional self-potentiating mechanisms 
have also been described [15].  
 Due to a low oral bioavailability of only 10% [16], gemcitabine is administered as an 
intravenous infusion, typically over 30 min at a dose of 1000 – 1250 mg/m2 once per week 
[17]. The factors limiting gemcitabine’s oral bioavailability have been explored in humans 
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and mice. One study in humans highlighted the extensive first-pass metabolism of 
gemcitabine to 2′,2′-difluoro-2′-deoxyuridine (dFdU), via cytidine deaminase, after oral 
dosing of drug [16]. This study, however, quantified neither the fraction of drug absorbed 
from the intestinal lumen nor the fraction of drug that escaped presystemic metabolism in 
the gastrointestinal tract and/or liver. Studies in mice showed that tetrahydrouridine, a 
potent inhibitor of cytidine deaminase, could increase the oral bioavailability of 
gemcitabine from 10% to 40% [18]. However, while showing an improvement in the 
systemic availability of orally administered gemcitabine due to enzymatic inactivation, the 
intestinal permeability and mechanism of oral drug absorption were not studied.   
 Clearly, an orally administrable form of gemcitabine would benefit patients by 
providing a noninvasive, patient friendly, and cost-effective alternative to intravenous drug 
infusions while enabling greater flexibility in optimization of the dosing regimen. In 
particular, the intestinal absorption of gemcitabine has never been investigated 
systematically, even though gemcitabine is a substrate of several intestinally expressed 
nucleoside transporters [5]. Moreover, many in vitro systems (e.g., Caco-2 cells) used for 
perfunctory evaluation of gemcitabine intestinal permeability will likely provide 
misleading results as low expression levels of nucleoside transporters in these cells prevent 
an accurate evaluation of potential transporter-mediated uptake [19]. On the other hand, 
mice and humans show similar intestinal expression of nucleoside transporters [20], 
suggesting that appropriate mouse models (e.g., in situ intestinal perfusions) would better 
reflect the oral absorption of gemcitabine in humans as compared to cell culture systems. 
 With this knowledge gap in mind, the primary goals of this study were to characterize 
the mechanisms of gemcitabine intestinal permeability, the potential for saturation of 
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intestinal gemcitabine uptake, and the transporter(s) responsible for mediating the oral 
absorption of gemcitabine using in situ single-pass intestinal perfusions in mice.  
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3.3 Materials and Methods 
3.3.1 Chemicals 
 Gemcitabine, dilazep hydrochloride, thymidine, and high-performance liquid 
chromatography (HPLC) grade acetonitrile and trifluoroacetic acid (TFA) were purchased 
from Thermo Fisher Scientific (Waltham, MA). The deaminated gemcitabine metabolite 
dFdU was purchased from Sigma-Aldrich (St. Louis, MO). Radiolabeled gemcitabine 
(cytosine-2-14C) (55.0 mCi/mmol), subsequently referred to as [14C]-gemcitabine, was 
purchased from Moravek, Inc. (Brea, CA). CytoScint™ scintillation solution was purchased 
from MP Biomedicals, LLC (Solon, OH). Hyamine hydroxide was purchased from 
PerkinElmer (Waltham, MA). All other chemicals were obtained from standard 
commercial sources.   
3.3.2 Animals  
 Studies were performed on 8- to 12-week old gender matched C57BL/6 mice. The 
mice were housed and bred in a temperature-controlled room with 12-hour light/dark 
cycles and ad libitum access to water and a standard diet (Unit for Laboratory Animal 
Medicine, University of Michigan, Ann Arbor, MI). Limited validation studies were also 
performed in 8- to 12-week old female BALB/c mice (Charles River Laboratories, 
Wilmington, MA). All animal studies were conducted in accordance with the Guide for the 
Care and Use of Laboratory Animals.  
3.3.3 In situ single-pass intestinal perfusions 
 Intestinal perfusions in C57BL/6 and BALB/c mice were performed identically and 
as previously described [21-23]. Prior to experimentation, mice were fasted overnight (~ 
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16 hr) with free access to water. The mice were then anesthetized with sodium 
pentobarbital (40 - 60 mg/kg intraperitoneal) and placed on a heating pad to maintain body 
temperature. The abdominal region was sterilized with 70% ethanol and the intestines 
exposed via a mid-line abdominal incision. An 8 cm jejunal segment, beginning 2 cm distal 
from the Ligament of Treitz, was isolated and glass cannulas (2.0 mm outer diameter) were 
inserted into each end of the segment and secured with silk sutures. The cannulated 
segment was rinsed with isotonic saline solution (or distilled water in experiments using 
sodium-free buffer) to remove debris. The mice were then transferred to a 31℃ 
temperature controlled chamber and their abdomen covered with saline-wetted gauze and 
parafilm to prevent dehydration. Inlet tubing connected the proximal cannula to a 20 mL 
syringe containing the perfusion solution and positioned in a perfusion pump (PHD Ultra, 
Harvard Apparatus, South Natick, MA). Outlet tubing connected the distal cannula to a 
collection vial.  
 The perfusion solution (pH 6.0) contained 145 mM NaCl, 0.5 mM MgCl2, 1 mM 
NaH2PO4, 1 mM CaCl2, 3 mM KCl, 5 mM glucose, 5 mM 2-morpholinoethanesulfonic 
acid (MES), and a given concentration of gemcitabine or [14C]-gemcitabine. This solution 
was perfused through the cannulated jejunal segment at 0.1 ml/min for a total of 90 min. 
After perfusing for 30 min to achieve steady-state conditions, samples of the exiting 
perfusate were collected at 10 min intervals for the remaining 60 min. Following 
experimentation, the precise length of the perfused jejunal segment was determined. Inlet 
and outlet samples collected during perfusion of gemcitabine were then analyzed using 
ultra-performance liquid chromatography (UPLC), as described and validated below. 
Samples collected during perfusion of [14C]-gemcitabine were analyzed by adding 100 µl 
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aliquots to scintillation vials containing 6.0 mL of scintillation solution and quantifying 
radioactivity using a dual-channel liquid scintillation counter (Beckman LS 6000 SC, 
Beckman Coulter Inc., Fullerton, CA).  
 Perfusions of 100 µM gemcitabine and 100 µM [14C]-gemcitabine (0.5 µCi) were 
performed in C57BL/6 mice and perfusions of 100 µM gemcitabine were performed in 
BALB/c mice. Concentration-dependent uptake studies were conducted in C57BL/6 mice 
by perfusing gemcitabine at concentrations ranging from 0.5 - 2000 µM. Specificity (i.e., 
inhibition) studies, also in C57BL/6 mice, were performed by perfusing 5 µM gemcitabine 
in the absence and presence of 2 mM thymidine or dilazep. An additional specificity study 
was performed in C57BL/6 mice by perfusing 5 µM gemcitabine in sodium-free buffer, 
prepared by replacing NaCl and NaH2PO4 in the perfusion solution with equimolar 
concentrations of N-methyl-D-glucamine and KH2PO4, respectively. Finally, 
concentration-dependent inhibition studies were performed in C57BL/6 mice where 5 µM 
gemcitabine was coperfused over a wide range of inhibitor concentrations for thymidine 
(0.1 - 2000 µM) and dilazep (0.1 - 2500 µM).  
3.3.4 Blood and intestinal tissue collections 
 Portal venous blood and intestinal tissue samples were collected from C57BL/6 mice 
following a standard 90 min perfusion of 5 µM [14C]-gemcitabine (0.5 µCi) alone and in 
the presence of 2 mM dilazep. Radioactivity was determined in portal venous plasma (nM 
levels) by adapting a previously described method [22]. Thus, immediately following the 
perfusion, portal venous blood was collected into tubes containing K3-EDTA and 
centrifuged for 3 min at 3000 rpm. A 30 µl plasma aliquot was then combined with 6.0 mL 
of scintillation solution and 20 µL of 0.5 N acetic acid and analyzed using a dual-channel 
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liquid scintillation counter (Beckman LS 6500 SC, Beckman Coulter Inc., Fullerton, CA). 
Likewise, radioactivity in intestinal tissue (pmol/mg) was determined by adapting a 
previously described method [24]. Following collection of portal venous blood, a jejunal 
segment was excised, washed with saline for 20 sec, blotted dry on filter paper, weighed, 
and soaked for 2 days in 0.33 mL of hyamine hydroxide at 37℃. Subsequently, 40 µL of 
30% H2O2 was added to the tissue sample which was then incubated for 30 min at 60℃.  
After cooling to room temperature, 6.0 mL of scintillation solution and 20 µL of 0.5 N 
acetic acid were added to the sample which was then analyzed using a dual-channel liquid 
scintillation counter (Beckman LS 6500 SC, Beckman Coulter Inc., Fullerton, CA).  
3.3.5 UPLC analytical method and validation 
 Inlet and outlet perfusate samples, other than those containing [14C]-gemcitabine, 
were assayed for gemcitabine, dFdU, and cytosine using a Waters Acquity H-Class UPLC 
system (Milford, MA) equipped with a photodiode array detector. dFdU was assayed since 
it is the primary metabolite of gemcitabine [25], whereas cytosine was reported to be 
formed as a gemcitabine metabolite during mouse intestinal perfusions [26]. The analytes 
were resolved at 40℃ on an Acquity HSS T3 column (2.1 x 100 mm), fitted with an HSS 
T3 VanGuard precolumn (2.1 x 5 mm). Separation was achieved using a gradient elution 
method combining water (plus 0.1% TFA) and acetonitrile (plus 0.1% TFA) at a flow rate 
of 0.4 ml/min. The solvent gradient was initiated at 100% water, decreased to 94% water 
linearly from 0.0 - 3.0 min, decreased to 85% water linearly from 3.0 – 5.0 min, increased 
to 100% water linearly from 5.0 – 6.0 min, and held at 100% water until the end of the run 
(8.0 min). Prior to analysis, perfusate samples were centrifuged for 15 min at 15000 rpm 
and 5 µl of the supernatant was subsequently injected onto the column via an autosampler. 
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Under these conditions, gemcitabine (detection wavelength = 284 nm) eluted at ~ 3.0 min, 
dFdU (detection wavelength = 265 nm) at ~ 4.2 min, and cytosine (detection wavelength 
= 284 nm) at ~ 1.0 min.  
 Selectivity of the assay was evaluated by analyzing perfusion outlet samples, 
collected following perfusion of blank perfusion buffer, with the three analytes at their 
lower limits of quantitation (i.e., 0.25 µM gemcitabine, 0.25 µM dFdU, and 1 µM cytosine) 
to assess for potential interferences. Linearity was evaluated by developing standard curves 
for gemcitabine (concentration range: 0.25 µM - 100 µM), dFdU (concentration range: 
0.25 µM - 5 µM), and cytosine (concentration range: 1 µM - 100 µM). Intra- and inter-day 
accuracy and precision were evaluated by analyzing quality control samples of gemcitabine 
(0.25 µM, 25 µM, and 100 µM), dFdU (0.25 µM, 1 µM, and 5 µM), and cytosine (1 µM, 
50 µM, and 100 µM) in triplicate on three separate days. 
3.3.6 Data analysis 
 The effective permeability (Peff) of gemcitabine was calculated according to the 
parallel tube complete radial mixing model [27]: 
 
 
𝑃𝑃𝑒𝑒𝑒𝑒𝑒𝑒 = −𝑄𝑄𝑖𝑖𝑖𝑖  ∙  ln �𝐶𝐶𝑜𝑜𝑜𝑜𝑜𝑜′𝐶𝐶𝑖𝑖𝑖𝑖 �2𝜋𝜋𝜋𝜋𝜋𝜋  (Eq 3.1) 
 
where 𝑄𝑄𝑖𝑖𝑖𝑖 represents the inlet flow rate of perfusion buffer (0.1 ml/min), 𝐶𝐶𝑜𝑜𝑜𝑜𝑜𝑜′  the total 
outlet concentration of all drug species, after correcting for intestinal water flux, 𝐶𝐶𝑖𝑖𝑖𝑖 the 
inlet gemcitabine concentration, R the intestinal radius of the perfused segment (0.1 cm), 
and L the length of the perfused segment. Using the gravimetrically determined outlet flow 
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rate (𝑄𝑄𝑜𝑜𝑜𝑜𝑜𝑜), and the measured outlet concentrations of gemcitabine (𝐶𝐶𝑜𝑜𝑜𝑜𝑜𝑜,𝑔𝑔𝑒𝑒𝑔𝑔𝑔𝑔𝑖𝑖𝑜𝑜𝑜𝑜𝑔𝑔𝑖𝑖𝑖𝑖𝑒𝑒) 
and 𝑑𝑑𝐹𝐹𝑑𝑑𝑑𝑑 (𝐶𝐶𝑜𝑜𝑜𝑜𝑜𝑜,𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑), 𝐶𝐶𝑜𝑜𝑜𝑜𝑜𝑜′  was calculated according to Eq 3.2 [28].  
 
 𝐶𝐶𝑜𝑜𝑜𝑜𝑜𝑜′ = (𝐶𝐶𝑜𝑜𝑜𝑜𝑜𝑜,𝑔𝑔𝑒𝑒𝑔𝑔𝑔𝑔𝑖𝑖𝑜𝑜𝑜𝑜𝑔𝑔𝑖𝑖𝑖𝑖𝑒𝑒 + 𝐶𝐶𝑜𝑜𝑜𝑜𝑜𝑜,𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑)  ∙  �𝑄𝑄𝑜𝑜𝑜𝑜𝑜𝑜𝑄𝑄𝑖𝑖𝑖𝑖 � (Eq 3.2) 
 
Importantly, when calculating gemcitabine Peff following [14C]-gemcitabine perfusion, 𝐶𝐶𝑖𝑖𝑖𝑖 
corresponded to the inlet radioactivity concentration and 𝐶𝐶𝑜𝑜𝑜𝑜𝑜𝑜′  the outlet radioactivity 
concentration, after correcting for intestinal water flux as described above. 
 The steady-state flux (J) of gemcitabine was calculated as: 
 
 𝐽𝐽 = 𝑃𝑃𝑒𝑒𝑒𝑒𝑒𝑒  ∙  𝐶𝐶𝑖𝑖𝑖𝑖 (Eq 3.3) 
 
 The concentration-dependent flux of gemcitabine was best fit to an equation 
consisting of two Michaelis-Menten (i.e., saturable) terms:  
 
 𝐽𝐽 = 𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚,1 ∙ 𝐶𝐶𝑖𝑖𝑖𝑖𝐾𝐾𝑚𝑚,1 + 𝐶𝐶𝑖𝑖𝑖𝑖 + 𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚,2 ∙ 𝐶𝐶𝑖𝑖𝑖𝑖𝐾𝐾𝑚𝑚,2 + 𝐶𝐶𝑖𝑖𝑖𝑖   (Eq 3.4) 
 
where 𝑉𝑉𝑔𝑔𝑜𝑜𝑚𝑚,1 and 𝑉𝑉𝑔𝑔𝑜𝑜𝑚𝑚,2 correspond to the maximum uptake rates for transport systems 1 
and 2, and 𝐾𝐾𝑔𝑔,1 and 𝐾𝐾𝑔𝑔,2  correspond to the Michaelis constants for transport systems 1 
and 2, referenced to inlet drug concentrations.     
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 Concentration-dependent inhibition data were normalized (i.e., gemcitabine flux 
expressed as percent of control) and fit to Eq 3.5 for thymidine inhibition or to Eq 3.6 for 
dilazep inhibition:  
 
 
𝑌𝑌 = 100 × � 𝐼𝐼𝐶𝐶50
𝐼𝐼𝐶𝐶50 +  𝐼𝐼� (Eq 3.5) 
 
𝑌𝑌 = 𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 + (100 − 𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵) × � 𝐼𝐼𝐶𝐶50
𝐼𝐼𝐶𝐶50 + 𝐼𝐼�  
 
(Eq 3.6) 
 
where 𝐼𝐼𝐶𝐶50 corresponds to the half maximal inhibitory concentration, 𝐼𝐼 to the inhibitor 
concentration of thymidine or dilazep, and 𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 to the residual flux of 5 µM 
gemcitabine at maximum inhibition.  
 Data were reported as mean ± SE. When comparing two groups, statistical differences 
were evaluated using an unpaired t-test. Statistical differences between three or more 
groups were evaluated by one-way ANOVA followed by Dunnett’s test for pairwise 
comparisons (Prism version 7, GraphPad Software, La Jolla, California). A p value ≤ 0.05 
was considered significant. Nonlinear regression was performed using GraphPad Prism 
software and the quality of fits was evaluated using the coefficient of determination (r2), 
visual inspection of the residuals, variation of the parameter estimates, and the corrected 
Akaike information criterion (AICc) [29]. 
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3.4  Results 
3.4.1  UPLC method validation 
 Selectivity of the assay was confirmed by analyzing outlet perfusate samples 
collected during perfusion of drug-free perfusion solution, showing no significant 
interference of co-eluting peaks on analysis of the three analytes at their lower limits of 
quantitation. Next, standard curve linearity was confirmed for gemcitabine (r2 = 1.000), 
dFdU (r2 > 0.999), and cytosine (r2 > 0.999). Finally, as seen in Table 3.1, the assay showed 
excellent intra- and inter-day accuracy and precision.   
3.4.2 Verification of experimentally-determined intestinal permeability  
 Following the intestinal perfusion of 100 µM gemcitabine in C57BL/6 and BALB/c 
mice, outlet perfusate samples contained gemcitabine and low concentrations of dFdU (< 
3%). Cytosine was absent in outlet samples following perfusion in both strains (Figure 3.1). 
To further support our results (i.e., no other metabolites were being formed), additional 
intestinal perfusions were performed with 100 µM [14C]-gemcitabine in C57BL/6 mice. As 
shown in Figure 3.2, the effective permeability (Peff) of 100 µM gemcitabine in C57BL/6 
mice was not different between the two analytical methods, with average Peff values of 1.14 
x 10-4 cm/s when analyzed by UPLC and 1.05 x 10-4 cm/s when analyzed by radioactivity. 
These results validate the analytical methods applied in the current study and demonstrate 
that gemcitabine metabolites are not confounding the findings.  
3.4.3 Concentration-dependent uptake studies 
 To explore the potential for saturation of gemcitabine intestinal uptake, in situ jejunal 
perfusions were performed in C57BL/6 mice at 14 concentrations ranging from 0.5 µM to 
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2 mM. As shown in Figure 3.3, gemcitabine displayed saturable kinetics, where the flux 
was best described by two Michaelis-Menten terms (Table 3.2). Thus, a high-affinity, low-
capacity transport system was identified (Vmax,1 and Km,1) along with a low-affinity, high-
capacity transport system (Vmax,2 and Km,2). Examination of the data using a Wolf-
Augustinsson-Hofstee plot (Figure 3.4) shows clear deviation from linearity, providing 
further evidence that two distinct absorption mechanisms are mediating the intestinal 
uptake of gemcitabine. As a result, subsequent studies were performed using inlet 
gemcitabine concentrations of 5 µM to ensure linear conditions.  
3.4.4 Inhibition Studies 
 To elucidate the transporter(s) responsible for mediating the intestinal permeability 
of gemcitabine in C57BL/6 mice, 5 µM gemcitabine was perfused in a sodium-containing 
buffer with either 2 mM thymidine (which can broadly inhibit the nucleoside transporters) 
or dilazep (which can inhibit the nucleoside transporters ENT1 and ENT2), or in a sodium-
free buffer (which can inhibit the nucleoside transporters CNT1 and CNT3). As shown in 
Figure 3.5, the jejunal permeability of gemcitabine was reduced by about 95% when 
coperfused with 2 mM thymidine (i.e., residual permeability = 4.6%) and by > 65% when 
perfused in a sodium-free buffer (i.e., residual permeability = 31.7%). Moreover, 2 mM 
dilazep coperfusion reduced the jejunal permeability of gemcitabine by about 50% (i.e., 
residual permeability = 50.2%). Additional studies were performed in C57BL/6 mice to 
examine the concentration-dependent inhibition of 5 µM gemcitabine flux by thymidine 
and dilazep. As shown in Figure 3.6, thymidine and dilazep inhibited gemcitabine flux with 
IC50 values of 98.5 µM and 212 µM, respectively. Taken together, these results 
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demonstrate that the intestinal permeability of gemcitabine is mediated almost exclusively 
by nucleoside transporters, with contributions by both the CNTs and ENTs.  
3.4.5 Accumulation of gemcitabine in intestinal tissue and portal venous plasma 
 In this study, 5 µM [14C]-gemcitabine was perfused in both the absence and presence 
of 2 mM dilazep (i.e., an ENT1 and ENT2 inhibitor) for 90 min in C57BL/6 mice, at which 
time jejunal tissue and portal venous blood samples were obtained. As shown in Figure 
3.7, total gemcitabine radioactivity in intestinal tissue was not altered by coperfusion with 
dilazep. However, total gemcitabine radioactivity in portal venous plasma decreased by > 
65% (i.e., % control = 32.5%).   
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3.5 Discussion 
 Various delivery techniques have been explored to increase the oral bioavailability 
of gemcitabine including the drug’s formulation as a prodrug [26, 30-32], its incorporation 
into polymeric microparticulates [33], nanoparticles [34, 35], and a self-microemulsifying 
drug delivery system [36], and its coadministration with a cytidine deaminase inhibitor 
[18]. Many of these studies aimed to increase the oral bioavailability of gemcitabine, at 
least partly, by increasing the drug’s purported low intestinal permeability [26, 30, 32-35]. 
Our studies indicated that the tenet of gemcitabine having low intestinal permeability was 
unfounded and, as a result, we decided to systematically characterize the drug’s mechanism 
of intestinal absorption, its potential for saturable intestinal uptake, and the mechanism(s) 
by which gemcitabine may transit through enterocytes. In doing so, our studies revealed 
several major findings, for the first time, including that: 1) at low concentrations, 
gemcitabine was a high-permeability drug in the intestine; 2) the jejunal uptake of 
gemcitabine was saturable and mediated almost exclusively by nucleoside transporters (> 
95%); 3) the jejunal flux of gemcitabine was mediated by two distinct transport systems, 
one being of high-affinity and low-capacity (i.e., CNTs) and the other being of low-affinity 
and high-capacity (i.e., ENTs); and 4) apically-expressed CNT(s) and ENT(s) mediate the 
uptake of gemcitabine into enterocytes, whereas basolaterally-expressed ENT(s) mediate 
the efflux of gemcitabine from enterocytes into portal venous blood.  
 The in situ jejunal permeability (Peff)  of gemcitabine was high in C57BL/6 mice (i.e., 
1.5 - 1.9 x 10-4 cm/s at 5 µM, Figure 3.5; and 1.1 x 10-4 cm/s at 100 µM, Figure 3.2) and 
on the order of other compounds we studied with high intestinal permeability. For example, 
previous work from our group utilizing the same experimental setup reported the Peff of 
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glycylsarcosine was 1.7 x 10-4 cm/s [37], the Peff of cefadroxil was 0.6-0.8 x 10-4 cm/s [21, 
22], the Peff of valacyclovir was 0.9 x 10-4 cm/s [23], and the Peff of 5-aminolevulinic acid 
was 1.9 x 10-4 cm/s [38]. To place these results in context, Escribano et al. reported that 
Peff values of about > 0.7 x 10-4 cm/s in mice will result in a fraction absorbed of > 90% 
following oral dosing in human [39]. The discrepancy between our current results with 
gemcitabine using in situ mouse perfusions (i.e., high permeability) and those using in vitro 
Caco-2 cells (i.e., low permeability) probably reflects the low expression of nucleoside 
transporters in these cell cultures [19] as well as the unphysiologic nature of in vitro 
systems lacking a blood supply. Interestingly, Tsume et al. [26] performed similar in situ 
jejunal perfusion studies with 100 µM gemcitabine in female BALB/c mice, but reported 
the drug to have low intestinal permeability. Specifically, their reported Peff value of 0.02 
x 10-4 cm/s for gemcitabine was >50-fold lower than the value observed in our current 
study at the same drug concentration in mixed-gender C57BL/6 mice (no gender bias 
noted). Potential strain differences in gemcitabine Peff were evaluated in the current study, 
where the Peff of 100 µM gemcitabine was not different between C57BL/6 mice (1.14 ± 
0.08 x 10-4 cm/s) and BALB/c mice (1.09 ± 0.13 x 10-4 cm/s). Thus, we attribute this 
“apparent” discrepancy between the current work and the previously published work to the 
fact that previous investigators [26] corrected gemcitabine Peff for the cytosine metabolite 
found in their outlet samples. In contrast, no evidence of cytosine was observed in the outlet 
samples during our jejunal perfusions of gemcitabine in both C57BL/6 and BALB/c mice 
(Figure 3.1).   
 To further validate the UPLC analytical technique used in the current work (i.e., 
verify all drug related metabolites were being correctly quantified), perfusions were 
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performed in C57BL/6 mice using radiolabeled gemcitabine (i.e., [14C]-gemcitabine). 
Thus, the total concentration of drug and drug-related species in the inlet and outlet samples 
could be determined by simply measuring total radioactivity, without the need to specify 
and quantify all potential gemcitabine metabolites(s) individually. The [14C]-label was 
present on the cytosine moiety of gemcitabine, thereby ensuring detection of any perfused 
gemcitabine present in the outlet as cytosine. We found no significant difference in the 
jejunal permeability when samples were analyzed via radioactivity and UPLC (i.e., <10%, 
Figure 3.2), indicating that the UPLC assay was correctly identifying all relevant 
gemcitabine metabolites and that gemcitabine is, in fact, highly permeable in the intestine. 
Thus, it appears that previous investigators [26] reported an HPLC peak that was 
incorrectly identified as a gemcitabine metabolite, causing a substantial underestimation of 
gemcitabine permeability. No such peak was observed in our assay for gemcitabine and 
metabolites using UPLC, which has improved resolution over HPLC.  
 The potential for saturation of gemcitabine’s intestinal uptake along with the drug’s 
transport kinetics were explored by evaluating the flux of gemcitabine over a large range 
of perfusate concentrations (i.e., 0.5 µM to 2 mM) in C57BL/6 mice. These experiments 
showed a clear saturation of intestinal flux (Figure 3.3), which was best described by two 
Michaelis-Menten terms. This mathematical fit (Table 3.2) suggested that both high-
affinity, low-capacity (Km = 27.4 µM, Vmax = 3.6 pmol/cm2/s) and low-affinity, high-
capacity (Km = 700 µM, Vmax = 35.9 pmol/cm2/s) transport systems mediated the intestinal 
uptake of gemcitabine. The existence of two distinct transport systems was further 
supported by clear nonlinearity in a Wolf-Augustinsson-Hofstee analysis of the 
concentration-dependent flux (Figure 3.4). Based on intrinsic clearance calculations, 
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Vmax/Km, the high- and low-affinity transport systems were predicted to account for 72% 
and 28% of the uptake, respectively, under linear conditions. However, as shown in Figure 
3.8, whereas the high-affinity transport system or CNTs dominated uptake at lower 
micromolar concentrations, the low-affinity transport system or ENTs dominated uptake 
at higher millimolar concentrations.  
 Broad inhibition of nucleoside transporters via coperfusion of 2 mM thymidine (IC50 
= 98.5 µM) reduced gemcitabine permeability by about 95% in C57BL/6 mice, showing 
that gemcitabine uptake is mediated almost exclusively via nucleoside transporters. 
Experiments in Xenopus laevis oocytes have reported Km values for gemcitabine transport 
via hCNT1 (Km ≈ 25 µM), hCNT3 (Km ≈ 60 µM), hENT1 (Km ≈ 160 µM), and hENT2 
(Km ≈ 750 µM) [7, 8]. These published Km values, along with our findings showing the 
presence of high- and low-affinity transport systems for gemcitabine (Table 3.2) and that 
both CNTs and ENTs mediate the intestinal uptake of gemcitabine (Figure 3.5), suggest 
that the high-affinity transport system in the current study corresponds to uptake via CNTs 
and the low-affinity transport system to uptake via ENTs. Furthermore, inhibition of CNTs 
in C57BL/6 mice (via perfusion with sodium-free buffer) reduced the intestinal 
permeability of gemcitabine by 68%, matching closely our predicted contribution of the 
high-affinity transport system (i.e., 72% of the total transport). Inhibition of ENTs in 
C57BL/6 mice, via coperfusion with 2 mM dilazep (IC50 = 212 µM), reduced the intestinal 
permeability of gemcitabine by about 50%, matching closely the predicted maximum 
dilazep mediated reduction in gemcitabine flux, based upon fitting the concentration-
dependent inhibition data (Figure 3.6). Still, dilazep’s reduction in gemcitabine flux was 
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greater than our predicted contribution of the low-affinity transport system (i.e., 28% of 
total transport), with the source of this disparity remaining unclear at present.    
 It is widely accepted that CNT1 and CNT3 are expressed apically in the small 
intestine, but there is some debate regarding the localization of ENT1 and ENT2 [5].  It has 
been reported that ENT2 is expressed primarily on the apical membrane of Caco-2 cells 
[40], that ENT1 and ENT2 are expressed on both the apical and basolateral membranes of 
human small intestine [41], and that ENT1 is expressed only on the basolateral membrane 
of human intestine [5]. It is important to consider that, although a low-affinity transport 
system was observed in the concentration-dependent flux data and that dilazep reduced 
gemcitabine’s intestinal permeability, this does not necessarily imply apical expression of 
ENT(s). Saturation/inhibition of basolateral ENT(s) could increase intracellular 
gemcitabine concentrations, leading to increased repartitioning of drug from the enterocyte 
to lumen, thereby reducing the intestinal permeability of drug. This possibility, however, 
seems improbable as gemcitabine possesses very low passive permeability (Figure 3.5) and 
thus is unlikely to repartition into the lumen to a significant extent without apical 
expression of the bidirectional ENT(s).  
 Previous studies have explored the duodenal expression of nucleoside transporter 
mRNA in ICR mice [20] and the longitudinal expression (i.e., stomach, duodenum, 
jejunum, ileum, large intestine) of nucleoside transporter mRNA in C57BL/6 mice [42]. 
These studies showed that the gene expression of CNTs and ENTs was similar between 
mouse and human, that CNTs were expressed primarily in small intestine, and that ENTs 
were expressed in both the small and large intestines, but at much lower levels than CNTs. 
To further address the localization of ENTs and to better understand their role in mediating 
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the intestinal uptake (i.e., lumen to enterocyte) and efflux (i.e., enterocyte to portal blood) 
of gemcitabine, intestinal perfusions of 5 µM [14C]-gemcitabine were performed in 
C57BL/6 mice (± the ENT inhibitor dilazep), after which total radioactivity was 
determined in jejunal tissue and portal venous plasma. Coperfusions with 2 mM dilazep 
reduced the intestinal permeability of gemcitabine by about 50% (Figure 3.5), showed no 
change in the cellular accumulation of gemcitabine radioactivity, and reduced the portal 
venous plasma concentration of gemcitabine radioactivity by 68% (Figure 3.7). These 
observations demonstrate that ENTs mediate, at least in part, the basolateral transport of 
gemcitabine into portal venous blood as gemcitabine’s efflux from enterocytes was 
substantially decreased by ENT inhibition. Still, despite the reduction of gemcitabine in 
portal venous plasma, the intracellular jejunal concentration of gemcitabine was not 
increased when coperfused with dilazep. This shows that gemcitabine’s reduction in 
intestinal permeability after ENT inhibition is not due to increased accumulation of 
gemcitabine in the intestinal tissue and passive repartitioning back into lumen, but a 
reduction in drug uptake into epithelial cells because of apically-expressed ENTs. A 
proposed schematic for the transepithelial flux of gemcitabine in the small intestine is 
presented in Figure 3.9.  
 There are currently no oral dosage forms of gemcitabine. Nonetheless, it is 
anticipated that typical intravenous doses of 1000 - 1250 mg/m2, given orally, would 
produce millimolar levels of drug in the intestinal lumen, favoring uptake by the ENTs. 
However, controlled-release or divided doses would serve to reduce the luminal 
concentrations of drug, thereby, taking advantage of both the CNTs and ENTs. Still, it 
would be important to determine how gemcitabine oral formulations and/or dose rates 
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might influence the drug’s presystemic metabolism in the gastrointestinal tract and/or liver, 
along with drug absorption.  
 In conclusion, novel approaches to develop orally-administered formulations of 
gemcitabine have been challenged by the drug’s perceived low intestinal permeability and 
significant presystemic metabolism. Our studies conclusively demonstrate that 
gemcitabine has, in fact, high permeability in the small intestine via CNT and ENT 
nucleoside transporters. Although gemcitabine should have low systemic availability after 
oral dosing, vectorial transport systems identified in the current study suggest that oral 
dosing (at the appropriate rate) may be advantageous for the selective targeting of 
gemcitabine to cancers of the intestine and liver. Furthermore, the demonstrated 
saturability of gemcitabine intestinal uptake highlights the importance of oral dosing rate 
in determining the fraction absorbed from the intestinal lumen, an important consideration 
for implementation of strategies aiming to enable oral gemcitabine administration by 
coadministration of a cytidine deaminase inhibitor.  
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Tables and Figures 
 
 
Table 3.1 Summary of intra- and inter-day accuracy and precision of the UPLC assay for 
quantification of gemcitabine, dFdU, and cytosine 
 
 
  Intra-day (n=3) Inter-day (n=9) 
Analyte Concentration (µM) 
Accuracy 
(%) 
Precision 
(CV%) 
Accuracy 
(%) 
Precision 
(CV%) 
Gemcitabine 0.25 / 25 / 100 106 / 100 / 100 1.2 / 0.1 / 0.2 98.1 / 100 / 100 8.7 / 0.3 / 0.5 
dFdU 0.25 / 1 / 5 98.4 / 101 / 100 4.1 / 0.8 / 0.5 98.9 / 100 / 100 3.8 / 0.8 / 0.8 
Cytosine 1 / 50 / 100 101 / 100 / 100 2.5 / 0.1 / 0.2 105 / 100 / 100 4.8 / 0.2 / 0.2 
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Table 3.2 Transport kinetics of gemcitabine during in situ jejunal perfusions in C57BL/6 
mice 
 
Parameter Estimate (mean ± SE) 
Vmax,1 (pmol/cm2/s) 3.6 ± 2.1 
Km,1 (µM) 27.4 ± 13.9 
Vmax,2 (pmol/cm2/s) 35.9 ± 5.5 
Km,2 (µM) 700 ± 330 
r2 0.951 
 
 
Gemcitabine flux was best fit to two saturable Michaelis-Menten terms where 𝑉𝑉𝑔𝑔𝑜𝑜𝑚𝑚,1 and 
𝑉𝑉𝑔𝑔𝑜𝑜𝑚𝑚,2 correspond to the maximum uptake rates for transport systems 1 and 2, and 𝐾𝐾𝑔𝑔,1 and 
𝐾𝐾𝑔𝑔,2  correspond to the Michaelis constants for transport systems 1 and 2 (see Eq 3.4).  
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Figure 3.1 Representative chromatograms demonstrating the absence of cytosine in outlet 
samples following in situ jejunal perfusion of 100 µM gemcitabine in (A) C57BL/6 mice 
and (B) BALB/c mice. The top panels show 5 µM cytosine standards and the bottom panels 
show perfusion outlet samples.  
 
 
  
 98 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 In situ jejunal permeability of gemcitabine in C57BL/6 mice when inlet and 
outlet concentrations of drug were measured by UPLC (after perfusions of 100 µM 
unlabeled gemcitabine) or total radioactivity (after perfusions of 100 µM [14C]-
gemcitabine). Data are expressed as mean ± SE, n=4. There was no significant difference 
between the two groups, as determined by unpaired t-test.  
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Figure 3.3 Concentration-dependent flux of gemcitabine during 0.5 µM - 2 mM in situ 
jejunal perfusions of drug in C57BL/6 mice. The solid line represents the predicted flux 
when data were fitted to two Michaelis-Menten terms. The inset shows the plot at low 
concentrations of gemcitabine. Data are expressed as mean ± SE, n=4 (error bars may be 
hidden by the symbol).  
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Figure 3.4 Wolf-Augustinsson-Hofstee analysis of the concentration-dependent flux of 
gemcitabine during 0.5 µM - 2 mM in situ jejunal perfusions of drug in C57BL/6 mice. 
Data are expressed as mean ± SE, n=4 (error bars may be hidden by the symbol).  
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Figure 3.5 Effect of inhibitors on the intestinal permeability of 5 µM gemcitabine during 
in situ jejunal perfusions of drug in C57BL/6 mice. Experiments with 2 mM thymidine and 
sodium-free buffer were performed several months before those with 2 mM dilazep and, 
as a result, control values were reported for each set of experiments. Data are expressed as 
mean ± SE, n=4. *** p<0.001 relative to control, as determined by ANOVA followed by 
Dunnett’s test for thymidine and sodium-free buffer data; and by unpaired t-test for dilazep 
data. There was no significant difference between the two control groups, as determined 
by unpaired t-test.   
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Figure 3.6 Concentration-dependent inhibition of gemcitabine flux in C57BL/6 mice 
during in situ jejunal perfusions of 5 µM drug alone and in the presence of (A) 0.1-2000 
µM thymidine or (B) 0.1-2500 µM dilazep. The solid line represents the predicted flux 
when data were fitted to Eq 3.5 for thymidine and to Eq 3.6 for dilazep. Data are expressed 
as mean, n=1-4.  
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Figure 3.7 Total radioactivity of gemcitabine and drug-related species in (A) jejunal tissue 
and (B) portal venous plasma following in situ jejunal perfusions of 5 µM [14C]-
gemcitabine in the absence and presence of 2 mM dilazep in C57BL/6 mice. Data are 
expressed as mean ± SE, n=4. ***p<0.001, as determined by unpaired t-test.  There was so 
significant difference detected in jejunal tissue radioactivity, as determined by an unpaired 
t-test.  
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Figure 3.8 Contribution of the high-affinity (CNTs) and low-affinity (ENTs) transport 
systems toward gemcitabine  flux, visualized over the three intestinal concentration ranges 
of (A) 0 – 100 µM, (B) 0 – 1,000 µM, and (C) 0 – 10,000 µM.  
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Figure 3.9 Proposed mechanism for the absorption of gemcitabine in small intestine. The 
apical uptake of gemcitabine (i.e., from lumen to enterocytes) is mediated by CNTs and 
ENTs, whereas the basolateral efflux of gemcitabine and/or gemcitabine metabolites (i.e., 
from enterocytes to portal venous blood) is mediated by ENTs.  
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CHAPTER 4  
Pharmacokinetics of Gemcitabine and its Amino Acid Ester Prodrug following Intravenous 
and Oral Administrations in Mice 
4.1 Abstract 
Gemcitabine is an intravenously administered anti-cancer nucleoside analogue. Systemic exposure 
following oral administration of gemcitabine is limited by extensive first-pass metabolism via 
cytidine deaminase (CDA) and potentially by saturation of nucleoside transporter-mediated 
intestinal uptake. An amino acid ester prodrug of gemcitabine, 5’-L-valyl-gemcitabine (V-Gem), 
was previously shown to be a substrate of the intestinally expressed peptide transporter 1 (PEPT1) 
and stable against CDA-mediated metabolism. However, preliminary studies did not evaluate the 
in vivo oral performance of V-Gem as compared to parent drug. In the present study, we evaluated 
the pharmacokinetics and in vivo oral absorption of gemcitabine and V-Gem following intravenous 
and oral administrations in mice. These studies revealed that V-Gem undergoes rapid systemic 
elimination (half-life < 1 min) and has a low oral bioavailability (< 1%). Most importantly, the 
systemic exposure of gemcitabine was not different following oral administration of equimolar 
doses of gemcitabine (gemcitabine bioavailability of 18.3%) and V-Gem (gemcitabine 
bioavailability of 16.7%). Single-pass intestinal perfusions with portal blood sampling in mice 
revealed that V-Gem undergoes extensive activation in intestinal epithelial cells and that 
gemcitabine undergoes first-pass metabolism in intestinal epithelial cells. Thus, formulation of 
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gemcitabine as the prodrug V-Gem does not increase systemic gemcitabine exposure following 
oral dosing, due, in part, to the instability of V-Gem in intestinal epithelial cells.  
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4.2 Introduction 
 Gemcitabine (2’,2’-difluoro-2’-deoxycytidine; dFdC) is a nucleoside analogue approved for 
use in the treatment of pancreatic, non-small cell lung, ovarian, and breast cancer [1]. It is also 
used off-label for treatment of other cancer types such as biliary tract and bladder cancer [2-4]. 
Gemcitabine exerts its anti-cancer activity through incorporation of gemcitabine triphosphate into 
growing DNA strands, inhibiting DNA synthesis [5] and leading to apoptosis [6]. Various self-
potentiating mechanisms, including gemcitabine diphosphate inhibition of ribonucleotide 
reductase [7], have been reported to augment gemcitabine cytotoxicity [8]. Gemcitabine is rapidly 
cleared from plasma (half-life = 42 – 94 min), mainly via cytidine deaminase (CDA)-mediated 
deamination of gemcitabine to 2’,2’-difluoro-2’-deoxyuridine (dFdU) [9]. The in vivo activity of 
dFdU is currently unclear, although some work has suggested it may contribute to gemcitabine 
cytotoxicity [10, 11] and radiosensitization [12].   
 Gemcitabine has a low oral bioavailability of about 10% [13] and is, thus, administered via 
intravenous infusion, typically once per week at a dose of 1000 – 1250 mg/m2 [1]. However, oral 
administration is generally preferred as it is more patient friendly, less invasive, and reduces the 
costs and complications associated with intravenous drug administration. Furthermore, oral 
gemcitabine administration would allow for greater flexibility in designing dosing schedules, 
enabling both metronomic gemcitabine dosing (i.e., frequent low dose administration) and dosing 
which replicates gemcitabine pharmacokinetics following a prolonged intravenous infusion. There 
is evidence that such dosing schedules may lead to improvements in efficacy and/or reductions in 
toxicity [14-17].  
 Given the advantages of oral gemcitabine administration, much work has been dedicated to 
understanding the mechanistic basis of gemcitabine’s low oral bioavailability. Recent work using 
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in situ intestinal perfusions in mice demonstrated that gemcitabine intestinal uptake is saturable 
and driven almost exclusively by nucleoside transporters (NT), and that gemcitabine has high 
effective permeability in the intestine, implying that first-pass metabolism drives gemcitabine’s 
low oral bioavailability [18]. This conclusion is further supported by the observation that following 
oral administration, gemcitabine undergoes extensive first-pass metabolism via CDA, forming 
dFdU [13]. Moreover, gemcitabine intestinal uptake is rapidly saturated with increasing 
concentration, which may further limit gemcitabine bioavailability following oral administration 
of larger and perhaps more clinically relevant doses [18].  
 In hopes of both increasing gemcitabine oral bioavailability by decreasing first-pass 
metabolism and enabling the oral administration of larger gemcitabine doses through reducing the 
saturability of gemcitabine intestinal absorption, several peptide transporter 1 (PEPT1)-targeted 
gemcitabine prodrugs were previously synthesized [19]. PEPT1 (SLC15A1) is a transmembrane 
transporter that is extensively expressed on the apical membrane of intestinal enterocytes [20]. 
Given that PEPT1 generally functions as a high-capacity, low-affinity intestinal transporter, it is 
frequently targeted to increase intestinal drug uptake via administration of a PEPT1-targeted 
prodrug. These prodrugs, often formed by addition of an amino acid to the parent molecule via an 
ester bond, undergo PEPT1-mediated uptake and are subsequently activated, releasing the active 
parent compound [21]. One such PEPT1-targeted gemcitabine prodrug, 5’-L-valyl-gemcitabine 
(V-Gem), was generated by linking l-valine to gemcitabine via an ester bond [19]. Previous in 
vitro work confirmed that V-Gem was stable against CDA-mediated deamination [19, 22] and was 
a PEPT1 substrate [19, 23].  
 With this in mind, the primary objective of this study was to characterize the in vivo 
pharmacokinetics of gemcitabine and V-Gem following intravenous and oral administrations in 
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mice. The secondary objective, using in situ intestinal perfusions in mice, was to evaluate the 
ability of V-Gem to reduce first-pass metabolism and increase intestinal drug absorption, relative 
to gemcitabine.  
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4.3 Materials and Methods 
4.3.1 Chemicals 
 Gemcitabine (Gem), high-performance liquid chromatography (HPLC) grade acetonitrile, 
and HPLC grade trifluoroacetic acid (TFA) were purchased from Thermo Fisher Scientific 
(Waltham, MA). Tetrahydrouridine (THU) and the deaminated gemcitabine metabolite 2’,2’-
difluorodeoxyuridine (dFdU) were purchased from Sigma-Aldrich (St. Louis, MO). 13C,15N2– Gem 
and 13C,15N2-dFdU internal standards were purchased from Toronto Research Chemicals (Toronto, 
Canada). The 5’-L-valyl-gemcitabine prodrug (V-Gem) was synthesized by AAPharmaSyn, LLC 
(Ann Arbor, MI). All other chemicals were obtained from standard commercial sources. See 
Figure 4.1 for the chemical structures of Gem, dFdU, and V-Gem. 
4.3.2 Animals  
 Studies were performed on 8- to 12-week old gender-matched C57BL/6 mice purchased from 
Charles River Laboratories (Wilmington, MA). The mice were housed in a temperature-controlled 
room with 12-hour light/dark cycles and were provided a standard diet with ad libitum access to 
water (Unit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, MI). All animal 
studies were conducted in accordance with the Guide for the Care and Use of Laboratory Animals.  
4.3.3 Intravenous and oral pharmacokinetic studies of Gem and V-Gem 
 For intravenous studies, mice were administered 76 nmol/g body weight of Gem or V-Gem 
(in 0.1 mL saline per 25 g body weight) via bolus tail vein injection (n=4). For oral studies, mice 
were fasted overnight (~ 16 hr) and subsequently administered 228 nmol/g body weight of Gem 
or V-Gem (in 0.2 mL water per 25 g body weight) via oral gavage (n=4). Following both 
intravenous and oral dosing, blood samples were collected via distal tail transection at 2, 5, 15, 30, 
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45, 60, 90, 120, 180, 240, 300, and 360 min. At each sampling time point, approximately 20 µL 
of blood was collected with a pipette, added to a 0.2 mL PCR tube containing EDTA-K3 and THU 
(the latter included to prevent ex vivo Gem deamination by CDA), and centrifuged at 3000 rpm for 
4 min at 4℃. A 5 µL plasma aliquot was then mixed with 200 µL ice-cold acetonitrile, containing 
0.1 µM 13C,15N2-Gem and 0.25 µM 13C,15N2-dFdU as internal standards (IS), and placed in the -
20℃ freezer until all samples for the given mouse were collected. Samples were then centrifuged 
at 17,000 g for 10 min at 4 ℃ and a 60 µL aliquot of the supernatant stored at -80℃ until analysis.  
 Afterwards, the supernatants were dried in a SpeedVac concentrator for two hours (with 
heating at 45 ℃ during the first hour) and reconstituted in 90 µL water (plus 0.1% formic acid). 
The reconstituted samples were centrifuged at 17,000 g for 10 min at 4℃ and the supernatants 
were analyzed via liquid chromatography-tandem mass spectrometry (LC-MS/MS), as described 
below. 
4.3.4 LC-MS/MS assay conditions for pharmacokinetic study samples 
 The concentrations of Gem, dFdU, and V-Gem were determined in mouse plasma samples 
using a novel LC-MS/MS method utilizing a Shimadzu HPLC system (Shimazu, Kyoto, Japan) 
coupled with an Applied Biosystems API 4000 triple quadrupole/linear ion trap (QTRAP) mass 
spectrometer (Foster City, CA). Following plasma sample collection and preparation (see above), 
8 µL of supernatant was injected onto an Agilent Poroshell 120 EC-C18 column (2.7 µm, 2.1 x 50 
mm, Santa Clara, CA). Analyte separation was achieved using a gradient elution method 
combining water (plus 0.1% formic acid) and acetonitrile (plus 0.1% formic acid) at a flow rate of 
0.35 mL/min. The gradient was initiated and held at 1% acetonitrile for 0.5 min, increased to 90% 
acetonitrile linearly from 0.5 – 1.0 min, held at 90% acetonitrile from 1.0 - 3.0 min, decreased to 
1% acetonitrile linearly from 3.0 - 3.1 min, and held at 1% acetonitrile until the end of the run (5.1 
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min). To minimize and monitor for carryover, injections of blank water were performed between 
all sample injections.  
 The MS was operated in a positive multiple reaction monitoring (MRM) mode using turbo 
electrospray ionization. The source-dependent parameters were set as follows: curtain gas 30 psi, 
ionspray voltage 5500 V, temperature 500 °C, gas1 50 psi and gas2 50 psi. The analyte-specific 
MS parameters are summarized in Table 4.1.  
4.3.5 Validation of LC-MS/MS assay for pharmacokinetic study samples 
 Calibrator, quality control (QC), and stability samples were prepared by performing a 10x 
dilution of aqueous drug solutions into blank mouse plasma. For all three analytes (i.e., Gem, 
dFdU, and V-Gem), calibrator samples were prepared at final concentrations of 0.05, 0.1, 0.25, 1, 
5, 20, 50, and 100 µM, QC samples at 0.1, 5, and 50 µM, and stability samples at 0.1, 2, 5, 50, and 
100 µM. The calibrator, QC, and stability samples were processed for analysis identically with 
plasma samples collected from the pharmacokinetic study (i.e., plasma quenched in acetonitrile 
containing IS, supernatant dried, dried sample reconstituted in water, supernatant analyzed).  
 Selectivity of the assay was evaluated by injecting blank plasma samples prepared from 
multiple mice, blank plasma spiked with IS, and blank plasma spiked with the three analytes at 
0.05 µM to assess potential interferences. Linearity was evaluated by developing standard curves 
ranging from 0.05 – 100 µM for all three analytes. 13C,15N2-dFdU was used as the IS for dFdU and 
13C,15N2-Gem was used as the IS for both Gem and V-Gem. Assay accuracy and precision were 
determined by analyzing QC samples in triplicate in three independent runs. Finally, sample 
stability was assessed during long-term storage by analyzing stability samples (2, 100 µM) after 
storage at -80 ℃ for 30 days. Autosampler stability was assessed by analyzing stability samples 
(0.1, 5, and 50 µM) after storage in the autosampler (4℃) for 24 hr.  
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4.3.6 In situ single-pass intestinal perfusions of Gem and V-Gem 
 Intestinal perfusions in mice were performed as previously described [18, 24]. In brief, mice 
were fasted overnight (~ 16 hr) with free access to water and subsequently anesthetized with 
sodium pentobarbital (40 – 60 mg/kg intraperitoneal). Their abdominal cavity was then exposed 
and an 8 cm long jejunal segment, beginning 2 cm distal from the Ligament of Treitz, was isolated 
and both ends cannulated. The proximal canula was attached to a syringe containing pH 6.0 
perfusion solution and positioned in a perfusion pump (PHD Ultra, Harvard Apparatus, South 
Natick, MA). The distal canula was connected to a collection vial.  
 The perfusion solution contained 145 mM NaCl, 5 mM morpholinoethanesulfonic acid 
(MES), 5 mM glucose, 3 mM KCl, 1 mM CaCl2, 1 mM NaH2PO4, 0.5 mM MgCl2, and either 100 
µM Gem or 100 µM V-Gem. To assess drug stability in the intestinal lumen, the perfusion solution 
containing Gem or V-Gem was perfused through the cannulated segment at 0.1 ml/min for 30 min 
to achieve steady-state, and then for an additional 60 min with outlet sample collections every 10 
min. The concentrations of Gem, dFdU, and V-Gem were determined in inlet and outlet samples 
using a previously described UPLC assay [18], revalidated for the quantification of an additional 
analyte, V-Gem (validation data not shown here).   
 Perfusion studies to explore drug stability in intestinal epithelial cells were also performed 
by perfusing perfusion solution, containing 10 mM Gem or 10 mM V-Gem, through the cannulated 
jejunal segment at 0.1 mL/min for 5 min and then immediately collecting a portal blood sample (~ 
200 ul). The portal blood sample was collected in a 1.5 mL microcentrifuge tube containing 
EDTA-K3 and THU, and immediately centrifuged at 3000 g for 4 minutes at 4 ℃. A 50 µl aliquot 
of plasma was then mixed with 200 µl of ice-cold acetonitrile (containing caffeine as an IS) and 
stored at -20 ℃ until all samples were collected. Samples were then centrifuged at 17,000 g for 10 
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min at 4 ℃ and 60 µL of the supernatant collected. The supernatants were then dried in a SpeedVac 
concentrator for two hours (with heating at 45 ℃ during the first hour) and reconstituted in 80 µL 
water (plus 0.1% TFA). The reconstituted samples were centrifuged at 17,000 g for 10 min at 4℃ 
and the supernatants analyzed via UPLC, as described below.  
4.3.7 UPLC assay for analysis of portal blood samples 
 The concentrations of Gem, dFdU, and V-Gem were determined in portal plasma samples 
using a Waters Acquity H-Class UPLC system (Milford, MA) coupled with a photodiode array 
detector. Following portal plasma collection and preparation (see above), 15 µl of supernatant was 
injected onto a 40℃ Acquity HSS T3 column (2.1 x 100 mm), fitted with an HSS T3 VanGuard 
precolumn (2.1 x 5 mm). Analyte separation was achieved using a gradient elution method 
combining water (plus 0.1% TFA) and acetonitrile (plus 0.1% TFA) at a flow rate of 0.4 ml/min. 
The gradient was initiated at 0% acetonitrile, increased to 6% acetonitrile linearly from 0 – 3 min, 
increased to 15% acetonitrile linearly from 3 – 5 min, increased to 80% acetonitrile linearly from 
5 – 7 min, held at 80% acetonitrile from 7 – 8 min, returned to 0% acetonitrile linearly from 8 – 9 
min, and held at 0% acetonitrile until the end of the run (12 min). Calibration curves ranging from 
the lower limit of quantiation to the upper limit of quantitation were generated for V-Gem (0.025 
– 5 µM, detection wavelength = 275 nm), Gem (0.1 – 50 µM, detection wavelength = 284 nm), 
and dFdU (0.1 – 50 µM, detection wavelength = 260 nm) using caffeine (detection wavelength = 
275 nm) as the IS. The method was validated with respect to selectivity, showing no endogenous 
compound interference with analyte detection, linearity (r2 > 0.991), accuracy (average bias of 
triplicated QC samples < 12%), and precision (relative standard deviation of triplicated QC 
samples < 7%).  
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4.3.8 Data analysis 
 Noncompartmental analysis (NCA) of plasma-concentration time profiles after oral and 
intravenous dosing was performed using Phoenix WinNonlin 8.2 (Certara, St. Louis, MO). All 
pharmacokinetic parameters were reported as geometric mean (geometric CV%) except for Tmax, 
which was reported as median (min – max). The bioavailability of Gem following oral Gem and 
V-Gem administrations was calculated as 𝐴𝐴𝑑𝑑𝐶𝐶𝐺𝐺𝐺𝐺𝑚𝑚,𝐺𝐺𝐺𝐺𝑚𝑚 𝑃𝑃𝑃𝑃
𝐴𝐴𝑑𝑑𝐶𝐶𝐺𝐺𝐺𝐺𝑚𝑚,𝐺𝐺𝐺𝐺𝑚𝑚 𝐼𝐼𝐼𝐼  ×  𝐷𝐷𝑜𝑜𝐷𝐷𝑒𝑒𝐼𝐼𝐼𝐼𝐷𝐷𝑜𝑜𝐷𝐷𝑒𝑒𝑃𝑃𝑃𝑃 and 𝐴𝐴𝑑𝑑𝐶𝐶𝐺𝐺𝐺𝐺𝑚𝑚,   𝐼𝐼−𝐺𝐺𝐺𝐺𝑚𝑚 𝑃𝑃𝑃𝑃𝐴𝐴𝑑𝑑𝐶𝐶𝐺𝐺𝐺𝐺𝑚𝑚,   𝐺𝐺𝐺𝐺𝑚𝑚 𝐼𝐼𝐼𝐼  ×  𝐷𝐷𝑜𝑜𝐷𝐷𝑒𝑒𝐼𝐼𝐼𝐼𝐷𝐷𝑜𝑜𝐷𝐷𝑒𝑒𝑃𝑃𝑃𝑃, 
respectively. When performing calculations with AUC values, AUCinf values were used unless the 
percent extrapolated was > 25%, in which case AUC0-6 hr values were used. All other data were 
reported as arithmetic mean ± SE, unless otherwise noted. When comparing two groups, statistical 
differences were evaluated using an unpaired t-test (Prism version 7, GraphPad Software, La Jolla, 
California). A p value ≤ 0.05 was considered significant.  
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4.4 Results 
4.4.1 LC-MS/MS assay validation for use in pharmacokinetic studies 
 Selectivity of the assay was demonstrated by injecting blank plasma samples from multiple 
mice, blank plasma spiked with IS, and blank plasma spiked with the analytes and IS. No 
significant interference of co-eluting peaks on analysis of the three analytes (i.e., Gem, dFdU, and 
V-Gem) and two IS (i.e., 13C,15N2– Gem and 13C,15N2– dFdU) was observed. Next, calibration 
curves ranging from 0.05 – 100 µM were developed for all analytes and shown to be linear (r2 > 
0.990). As shown in Table 4.2, the method showed excellent accuracy and precision in 
quantification of all analytes at low, medium, and high concentrations. Finally, sample stability 
was demonstrated for all analytes during long-term (30 days) storage at -80℃ (recovery range: 
102 – 111 %) and during short-term (24 hr) storage on the autosampler at 4℃ (recovery range: 
96.2 – 113 %).  
4.4.2 Pharmacokinetics following intravenous and oral Gem administrations 
 The mean plasma concentration-time profiles of Gem and dFdU are shown following 
intravenous administration of 76 nmol Gem/g body weight (Figure 4.2) and oral administration of 
228 nmol Gem/g body weight (Figure 4.3). Pharmacokinetic parameters for Gem and dFdU are 
summarized in Table 4.3. Following intravenous administration, Gem reached an initial 
concentration (C0 = Cmax) of 67.2 µM and was converted to dFdU, with the Tmax of dFdU occurring 
at 30 min. Following oral administration, Gem was rapidly absorbed reaching a maximum 
concentration (Cmax) of 9.8 µM at a Tmax of 30 min. The terminal half-life (T1/2) of Gem following 
intravenous Gem administration (42.5 min) was not different than the T1/2 after oral Gem 
administration (29.8 min) (p = 0.258). The T1/2 of dFdU was shorter following intravenous Gem 
administration (106 min), as compared to the T1/2 after oral Gem administration (210 min) (p = 
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0.050). Route-dependent differences were observed in the systemic exposure (i.e., AUC) ratios for 
dFdU/Gem, where the ratio was 1.5 after intravenous Gem dosing but 6.9 after oral Gem dosing.  
4.4.3 Pharmacokinetics following intravenous and oral V-Gem administrations 
 The mean plasma concentration-time profiles of Gem, dFdU, and V-Gem are shown 
following intravenous administration of 76 nmol V-Gem/g body weight (Figure 4.4) and oral 
administration of 228 nmol V-Gem/g body weight (Figure 4.5). Pharmacokinetic parameters for 
Gem, dFdU, and V-Gem are summarized in Table 4.3. Following intravenous V-Gem 
administration, V-Gem reached an initial concentration (C0 = Cmax) of 32.7 µM and was rapidly 
eliminated with a T1/2 of 3.7 min. Gem was rapidly formed with a Tmax occurring at the first 
sampling time point (2 min) in all mice. Systemic exposure of prodrug following intravenous V-
Gem administration was quite small relative to Gem (V-Gem to Gem AUC ratio = 0.13) and dFdU 
(V-Gem to dFdU AUC ratio = 0.05). Following oral V-Gem administration, the systemic exposure 
of prodrug was negligible (V-Gem oral to intravenous dose adjusted AUC ratio = 0.006) and Gem 
was rapidly formed, reaching a Cmax of 11.1 µM with a Tmax of 15 min. Again, the T1/2 of Gem 
following intravenous V-Gem administration (46.2 min) was not different than the T1/2 following 
oral V-Gem administration (39.1 min) (p = 0.406). However, the T1/2 of dFdU was shorter 
following intravenous V-Gem administration (128 min) as compared to oral V-Gem administration 
(216 min) (p < 0.001). Similar to Gem dosing, the average dFdU to Gem exposure ratio increased 
from 2.9 to 9.6 following intravenous and oral V-Gem dosing, respectively.  
4.4.4 V-Gem activation following intravenous V-Gem administration 
 As observed in Table 4.3, mean systemic Gem exposure was ≈ 50% lower following V-Gem 
intravenous administration (801 min x µM) relative to Gem intravenous administration (1628 min 
x µM) (p < 0.05). In contrast, mean systemic dFdU exposure was not different following V-Gem 
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intravenous administration (2345 min x µM) and Gem intravenous administration (2484 min x 
µM) (p = 0.848).   
4.4.5 Comparing systemic Gem and dFdU exposure following oral Gem and V-Gem 
administrations  
 As observed in Figure 4.6A, the mean plasma concentration-time profiles of Gem following 
oral Gem and V-Gem administrations are very similar. In fact, no statistically significant difference 
in Gem exposure exists following oral Gem administration (893 min x µM) and oral V-Gem 
administration (814 min x µM) (p = 0.594). Moreover, the bioavailability of Gem following oral 
Gem and V-Gem administrations are 18.3% and 16.7%, respectively. As shown in Figure 4.6B, 
the concentration-time profiles of dFdU are also similar following oral Gem and V-Gem 
administrations. Additionally, there is no statistically significant difference in dFdU exposure (p = 
0.084).  
4.4.6 Intestinal stability and absorption of Gem and V-Gem  
 Single-pass intestinal perfusions of Gem and V-Gem, with analysis of perfusion outlet 
samples, showed that < 1% of perfused Gem was found in outlet samples as dFdU and < 10% of 
perfused V-Gem was found in outlet samples as Gem. Furthermore, as shown in Figure 4.7, portal 
plasma concentrations of Gem, dFdU, and V-Gem were determined following 5 min perfusions of 
Gem and V-Gem. Following Gem perfusion, dFdU accounted for about 30% of the total drug 
found in portal plasma. Following V-Gem perfusion, V-Gem accounted for < 12% of the total drug 
found in portal plasma. Furthermore, total drug concentrations (i.e., Gem + dFdU + V-Gem) in 
portal plasma were no different following perfusions of either Gem or V-Gem (p = 0.608). 
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4.5 Discussion 
 With an oral bioavailability in humans of only 10%, gemcitabine’s therapeutic application is 
currently hindered by a reliance on intravenous administration [13]. Recent work using in situ 
intestinal perfusions in mice showed that the intestinal effective permeability of gemcitabine is 
high at low drug concentrations and rapidly decreases with increasing drug concentration as uptake 
via high-affinity nucleoside transporters becomes saturated [18]. Importantly, gemcitabine’s low 
systemic exposure following oral dosing was reported when gemcitabine was administered at low 
doses (≤ 8 mg) unlikely to saturate intestinal uptake [13], implying that first-pass metabolism of 
gemcitabine via cytidine deaminase (CDA) drives its low bioavailability. This conclusion is further 
supported by data in human and mouse showing that gemcitabine undergoes extensive presystemic 
deamination following oral administration, forming the deaminated gemcitabine metabolite dFdU 
[13, 25]. To decrease first-pass metabolism, and thus increase gemcitabine bioavailability, 
gemcitabine may be formulated as a prodrug which reduces the ability of CDA to bind and 
metabolize gemcitabine. For example, an l-valine ester gemcitabine prodrug, 5’-L-valyl-
gemcitabine (V-Gem) (Figure 4.1), was previously synthesized and shown to be stable against 
CDA mediated deamination, relative to gemcitabine, via incubations with recombinant human 
CDA [19, 22]. Furthermore, V-Gem was shown to be transported by peptide transporter 1 (PEPT1) 
[19, 23], a low-affinity, high-capacity transporter found on the apical membrane of intestinal 
enterocytes [21].  
 By formulating gemcitabine as a prodrug that confers stability against CDA-mediated first-
pass metabolism and is targeted to a high-capacity, low-affinity intestinal uptake transporter (i.e., 
PEPT1), V-Gem may both reduce first-pass gemcitabine metabolism and mitigate the potential for 
saturation of intestinal gemcitabine uptake. As a result, we decided to characterize the in vivo 
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pharmacokinetic performance of gemcitabine and V-Gem following intravenous and oral 
administrations in mice as well as the ability of V-Gem to reduce first-pass metabolism and 
increase drug absorption, relative to gemcitabine. In doing so, our studies revealed for the first 
time that: 1) V-Gem prodrug undergoes rapid systemic elimination (T1/2 < 4 min) and has very low 
oral bioavailability (<1%), 2) oral administration of V-Gem does not increase systemic exposure 
to gemcitabine, relative to oral gemcitabine administration, 3) V-Gem undergoes extensive first-
pass activation in intestinal epithelial cells, and 4) gemcitabine undergoes first-pass metabolism in 
intestinal epithelial cells.  
 Using a novel and validated LC-MS/MS assay, the concentration-time profiles of  
gemcitabine, dFdU, and V-Gem (following V-Gem administration) were determined in mice 
following intravenous administration of 76 nmol gemcitabine/g body weight, oral administration 
of 228 nmol gemcitabine/g body weight, intravenous administration of 76 nmol V-Gem/g body 
weight, and oral administration of 228 nmol V-Gem/g body weight. As shown in Table 4.3, the 
pharmacokinetic parameters describing gemcitabine disposition following intravenous and oral 
gemcitabine administrations are in agreement with previously reported values in mice [25]. 
Additionally, the initial gemcitabine concentration (C0 = Cmax) following intravenous 
administration of 76 nmol gemcitabine/g body weight (i.e., 20 mg gemcitabine/kg body weight) 
in mice was 67.2 µM, replicating the gemcitabine maximum concentration (Cmax)  of  50 – 70 µM 
following intravenous infusion of 1,250 mg gemcitabine/m2 in human [26]. It was observed that 
the metabolite (dFdU) to parent (gemcitabine) exposure ratio was >1 following both intravenous 
(ratio = 1.5) and oral (ratio = 6.9) gemcitabine administrations, reflecting the extensive conversion 
of gemcitabine to dFdU and the slow elimination of dFdU, relative to gemcitabine. This ratio was 
much higher following oral administration due to extensive presystemic conversion of gemcitabine 
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to dFdU, in accordance with previously published work [25, 27]. Interestingly, in previous studies 
reporting T1/2 values of dFdU in mice, there is substantial variability in both the calculated T1/2 and 
the length of time over which plasma samples were collected [25, 27-29]. Examining the mean 
concentration-time profile of dFdU in studies where plasma samples were collected for  ≥ 24 hr 
following gemcitabine administration [25, 29] suggests that the sampling scheme employed in the 
current study, which was designed to ensure adequate characterization of the concentration-time 
profile of gemcitabine, may bias downward estimates of dFdU T1/2. Thus, the statistically 
significant difference in dFdU T1/2 following oral gemcitabine administration (210 min) and 
intravenous gemcitabine administration (106 min) may be due to our sampling schedule being 
limited to six hours.  
 Following intravenous V-Gem administration, the prodrug rapidly disappeared from plasma 
with a T1/2 of 3.7 min, while gemcitabine rapidly appeared in plasma, with the gemcitabine Tmax 
occurring in the first sample (2 min) for all mice. Two enzymes, RBBP9 and the biphenyl 
hydrolase like enzyme (BPHL), have previously been shown to catalyze V-Gem activation in vitro 
via V-Gem incubations with these recombinant human enzymes [30, 31]. These studies, however, 
did not rule out the potential involvement of additional esterase enzymes in V-Gem activation. 
Interestingly, systemic gemcitabine exposure (AUCinf) was about 50% lower following 
intravenous V-Gem administration, relative to intravenous administration of an equimolar 
gemcitabine dose (p < 0.05). Total dFdU exposure (AUCinf), however, was not different following 
intravenous V-Gem and gemcitabine administrations. One potential explanation for this 
observation is that V-Gem is not completely activated to gemcitabine following intravenous 
administration but, instead, a portion of the administered V-Gem is first deaminated, forming 5’-
L-valyl-dFdU (V-dFdU), and V-dFdU is subsequently cleaved releasing dFdU. Given that 
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gemcitabine’s clearance and first-pass metabolism is driven by CDA-mediated deamination [9, 
13], the ability of V-Gem to reduce CDA-mediated deamination was tested and confirmed in vitro 
with recombinant human enzyme [19, 22]. However, it is feasible that V-Gem becomes a substrate 
of a different deaminase enzyme [32-35], whose activity on V-Gem has not been previously 
evaluated. It is also possible that V-Gem is stable against human, but not murine CDA. This species 
difference in CDA substrate specificity seems unlikely, however, as the amino acid residues 
believed to dictate CDA substrate specific are completely conserved between mouse and human 
CDA [36]. To confirm the hypothesized V-Gem metabolic scheme, verification of V-dFdU 
formation in vivo would be required. Regardless, the T1/2 of gemcitabine and dFdU following V-
Gem intravenous administration closely mirrored the corresponding values following gemcitabine 
intravenous administration.  
 The mean oral bioavailability of V-Gem was about 0.6% and, thus, systemic exposure to V-
Gem following oral administration was negligible. The mean plasma concentration-time profiles 
of gemcitabine following oral gemcitabine and V-Gem administrations (Figure 4.6A) are very 
similar, demonstrating that oral administrations of gemcitabine and V-Gem lead to equivalent 
systemic gemcitabine exposure. Quantitatively, this is evidenced by the fact that systemic 
gemcitabine exposure (AUCinf) following oral administration of gemcitabine (893 min x µM) and 
V-Gem (814 min x µM) were not statistically significantly different. In fact, the average 
gemcitabine exposure following oral V-Gem administration was about 9% lower. Gemcitabine 
oral bioavailability was 18.3% following oral gemcitabine administration, in line with previously 
reported values [25], and 16.7% following oral V-Gem administration. Interestingly, the 
concentration-time profile of dFdU appears to differ slightly following oral administrations of 
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gemcitabine and V-Gem (Figure 4.6B). However, there was no statistically significant difference 
in dFdU exposure following oral gemcitabine and V-Gem dosing.  
 To further understand why oral V-Gem administration did not increase systemic gemcitabine 
exposure, relative to oral gemcitabine administration, additional intestinal perfusion experiments 
were performed in mice. Importantly, for V-Gem to undergo PEPT1-mediated uptake and confer 
resistance against first-pass metabolism, it must be stable in both the stomach and the intestinal 
lumen. Previous work demonstrated V-Gem stability in pH 1.2 simulated gastric fluid (T1/2 > 120 
min) [23]. The stability of V-Gem in the intestinal lumen was explored in the current work by 
perfusing V-Gem through a cannulated jejunal segment in an anesthetized mouse and quantifying 
the concentration of activated gemcitabine in perfusion outlet samples. These experiments 
demonstrated that V-Gem underwent some activation in the intestinal lumen, however, < 10% of 
the perfused V-Gem was found in outlet samples as activated Gem.  
 Prodrug stability in intestinal epithelial cells was then explored by perfusing V-Gem for 5 
min and quantifying the concentration of gemcitabine, dFdU, and V-Gem in portal plasma samples 
(Figure 4.7). The short perfusion time was selected to minimize the impact of recirculated drug on 
the estimation of prodrug activation in intestinal epithelial cells. These results show that V-Gem 
undergoes extensive activation in intestinal epithelial cells as intact prodrug accounted for < 12% 
of total drug found in portal plasma. This observation is consistent with other work reporting 
extensive activation of amino acid ester prodrugs in mouse and rat intestinal epithelium [31, 37-
39]. Additionally, perfusion experiments were performed showing gemcitabine is quite stable in 
the intestinal lumen (< 1% of perfused gemcitabine found in outlet samples as dFdU) but 
undergoes first-pass metabolism in the intestinal enterocytes, as evidenced by the appearance of 
dFdU in portal plasma, accounting for about 30% of total drug. Thus, the extensive activation of 
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V-Gem in intestinal epithelial cells diminishes the ability of V-Gem to protect against first-pass 
gemcitabine metabolism in both the intestine and the liver and, thus, the ability of V-Gem to 
increase systemic gemcitabine exposure. Importantly, interspecies differences (i.e., mouse vs 
human) in the activity of various esterases have been reported, suggesting that V-Gem may be 
more stable in the human intestinal epithelium [40]. However, this seems unlikely given in vitro 
work showing that V-Gem undergoes extensive (> 90%) activation during transit through a Caco-
2 cell monolayer [19].  
 Furthermore, total drug concentrations in portal plasma samples following perfusion of 10 
mM gemcitabine and V-Gem were not different, indicating that even at high intestinal 
concentrations expected to completely saturate nucleoside transporter mediated gemcitabine 
uptake, partitioning of total drug from the intestinal lumen into portal plasma was not increased by 
V-Gem. An important caveat to this conclusion, however, is the assumption that no other V-Gem 
metabolites are present in portal plasma (e.g., V-dFdU). To address this possibility, perfusions 
with radiolabeled V-Gem could be performed and total drug concentrations in portal blood assayed 
via total radioactivity.  
 As alluded to above, the incomplete conversion of V-Gem to gemcitabine, which was 
hypothesized to occur following intravenous V-Gem administration, could also contribute to the 
inability of oral V-Gem administration to increase systemic gemcitabine exposure, relative to oral 
gemcitabine administration. However, it is important to note that incomplete V-Gem activation 
following intravenous V-Gem administration remains speculative and that V-Gem activation may 
differ following oral and intravenous administrations (i.e., V-Gem may undergo complete 
activation following oral but not intravenous administration). Thus, additional studies would be 
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needed to further explore V-Gem activation in vivo and the impact of potential incomplete 
activation on gemcitabine exposure following oral V-Gem administration.  
 In conclusion, the in vivo performance of a PEPT1-targeted gemcitabine prodrug, V-Gem, 
was evaluated following intravenous and oral administrations in mice. This work demonstrated 
that V-Gem is rapidly removed from plasma following intravenous administration and has very 
low oral bioavailability (< 1%). Furthermore, our studies demonstrate that formulation of 
gemcitabine as V-Gem did not lead to increased systemic gemcitabine exposure following oral 
dosing as gemcitabine bioavailability was no different following oral gemcitabine and V-Gem 
administrations. These results suggest that future prodrug strategies aimed at increasing systemic 
exposure of gemcitabine following oral dosing should focus on prodrugs with high intestinal 
effective permeability, good stability during first-pass transit through the intestinal enterocytes and 
liver, and complete conversion to the active gemcitabine species. Alternatively, future work aimed 
at enabling oral gemcitabine administration could focus on decreasing first-pass gemcitabine 
metabolism and, thus, increasing systemic gemcitabine exposure through co-administration of 
gemcitabine with a cytidine deaminase inhibitor.  
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Tables and Figures 
 
 
Table 4.1 Summary of analyte-specific mass spectrometry parameters 
 
Compound 
Parent  
Ion 
(m/z) 
Product  
Ion 
(m/z) 
Declustering 
Potential 
(V) 
Entrance 
Potential 
(V) 
Collision 
Energy 
(V) 
Collision 
Cell Exit 
Potential 
(V) 
Gem 264.0 112.0 60 12 26 13 
dFdU 265.0 113.0 60 12 22 13 
V-Gem 363.1 264.0 6 8 22 14 
13C,15N2-Gem (IS) 267.0 115.0 60 12 26 13 
13C,15N2-dFdU (IS) 268.0 116.0 60 12 22 13 
 
Gem, gemcitabine; dFdU, 2’,2’-difluorodeoxyuridine; V-Gem, 5’-L-valyl-gemcitabine; IS, 
internal standard. 
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Table 4.2 Summary of intra-day and inter-day accuracy and precision of the LC-MS/MS assay for 
quantification of Gem, dFdU, and V-Gem at low (0.1 µM), medium (5 µM), and high (50 µM) 
concentrations in mouse plasma 
 
  Intra-day (n=3) Inter-day (n=9) 
Analyte Concentration (µM) 
Accuracy 
(%) 
Precision 
(CV%) 
Accuracy 
(%) 
Precision 
(CV%) 
Gem 0.1 / 5 / 50 104 / 108 / 102 3.2 / 2.6 / 6.7 94 / 109 / 103 9.3 / 8.4 / 9.4 
dFdU 0.1 / 5 / 50 104 / 108 / 112 4.1 / 3.7 / 4.5 114 / 106 / 102 6.1 / 4.5 / 4.0 
V-Gem 0.1 / 5 / 50 107 / 91.1 / 102 2.9 / 12.3 / 6.4 112 / 90 / 108 11.3 / 10.4 / 4.0 
 
Gem, gemcitabine; dFdU, 2’,2’-difluorodeoxyuridine; V-Gem, 5’-L-valyl-gemcitabine. 
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Table 4.3 Pharmacokinetic parameters of Gem, dFdU, and V-Gem following IV (76 nmol/g) and 
PO (228 nmol/g) administrations of Gem and V-Gem in mice (n = 4) 
 
Treatment Parameter Analyte Gemcitabine dFdU Prodrug 
Gem IV           
(76 nmol/g) 
AUC0-6 hr (min x µM) 1621 (38%) 2218 (54%) - 
AUCinf (min x µM) 1628 (38%) 2484 (65%) - 
% Extrapolated 0.4 (40%) 8.2 (88%) - 
T1/2 (min) 42.5 (44%) 106 (32%) - 
Tmax (min) - 30 (30 - 45) - 
Cmax (µM) 67.2 (30%)† 15.5 (34%) - 
CL (mL/hr/g) 2.8 (38%) - - 
Vss (mL/g) 1.4 (44%) - - 
Gem PO              
(228 nmol/g) 
AUC0-6 hr (min x µM) 887 (55%) 6091 (15%) - 
AUCinf (min x µM) 893 (55%) 8613 (22%) - 
% Extrapolated 0.6 (55%) 26.2 (52%) - 
T1/2 (min) 29.8 (41%) 210 (41%) - 
Tmax (min) 30 (15 - 45) 45 (30 - 120) - 
Cmax (µM) 
Foral 
9.8 (42%) 
18.3% 
35.3 (30%) 
- 
- 
- 
V-Gem IV                       
(76 nmol/g) 
AUC0-6 hr (min x µM) 794 (23%) 2017 (49%) 103 (101%) 
AUCinf (min x µM) 801 (22%) 2345 (61%) 106 (98%) 
% Extrapolated 0.8 (92%) 11.3 (84%) 1.1 (253%) 
T1/2 (min) 46.2 (34%) 128 (38%) 3.7 (33%) 
Tmax (min) 2 (2 - 2) 22.5 (15 - 30) - 
Cmax (µM) 41.6 (26%) 13.9 (31%) 32.7 (139%)† 
CL (mL/hr/g) - - 43.1 (98%) 
Vss (mL/g) - - 2.4 (145%) 
V-Gem PO            
(228 nmol/g) 
AUC0-6 hr (min x µM) 806 (27%) 7732 (19%) 1.9 (113%) 
AUCinf (min x µM) 814 (27%) 11,125 (24%) CND 
% Extrapolated 0.9 (17%) 30.2 (13%) CND 
T1/2 (min) 39.1 (25%) 216 (9%) CND 
Tmax (min) 15 (5 - 30) 30 (15 - 30) 3.5 (2 - 5) 
Cmax (µM) 11.1 (24%) 47.9 (6%) 0.2 (101%) 
 Foral 16.7% - 0.6% 
Parameters are reported as geometric mean (geometric CV%), except for Tmax, which is reported 
as median (min – max), and oral bioavailability (Foral), which is reported as the dose normalized 
ratio (oral/IV) of the geometric mean AUCinf. †C0 reported for Cmax. CND, could not be 
determined; IV, intravenous; PO, oral; Gem, gemcitabine; dFdU, 2’,2’-difluorodeoxyuridine; V-
Gem, 5’-L-valyl-gemcitabine.   
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Figure 4.1 Structures of gemcitabine, the deaminated gemcitabine metabolite dFdU, and the 
gemcitabine prodrug 5’-L-valyl-gemcitabine. 
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Figure 4.2 Mean plasma concentration-time profiles of Gem and dFdU following intravenous (IV) 
administration of 76 nmol Gem/g body weight in mice. Data are expressed as mean ± SE (n=4) 
with the y-axis displayed on linear (left panel) and logarithmic (right panel) scales. 
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Figure 4.3 Mean plasma concentration-time profiles of Gem and dFdU following oral 
administration of 228 nmol Gem/g body weight in mice. Data are expressed as mean ± SE (n=4) 
with the y-axis displayed on linear (left panel) and logarithmic (right panel) scales. 
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Figure 4.4 Mean plasma concentration-time profiles of Gem, dFdU, and V-Gem following 
intravenous (IV) administration of 76 nmol V-Gem/g body weight in mice. Data are expressed as 
mean ± SE (n=4) with the y-axis displayed on linear (left panel) and logarithmic (right panel) 
scales.  
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Figure 4.5 Mean plasma concentration-time profiles of Gem, dFdU, and V-Gem following oral 
administration of 228 nmol V-Gem/g body weight in mice. Data are expressed as mean ± SE (n=4) 
with the y-axis displayed on linear (left panel) and logarithmic (right panel) scales. 
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Figure 4.6 Mean plasma concentration-time profiles following oral (PO) administration of 228 
nmol/g body weight Gem and V-Gem for (A) Gem and (B) dFdU. Data are expressed as mean ± 
SE (n=4) with the y-axis displayed on linear (left panel) and logarithmic (right panel) scales.  
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Figure 4.7 Portal plasma concentrations of Gem, dFdU, and V-Gem following 5 min jejunal 
perfusions of 10 mM Gem and V-Gem. The percent of total drug found as each analyte is also 
presented. Data are expressed as mean ± SE (n=4). Total drug concentrations were not significantly 
different following Gem and V-Gem perfusions, as determined by unpaired t-test. 
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CHAPTER 5  
Future Directions 
 It was previously believed that gemcitabine’s low oral bioavailability was due, at least in 
part, to inadequate intestinal absorption. However, this dissertation (Chapter 3) demonstrates that 
gemcitabine undergoes extensive nucleoside transporter-mediated absorption in mouse small 
intestine, implicating first-pass metabolism as the primary driver of low bioavailability. However, 
while mice are commonly used as a model system to study nucleoside transporter function in 
human and previous work concluded that the intestinal expression profile of nucleoside transporter 
mRNA is similar between mouse and human, translation of these findings to human has not been 
definitively demonstrated. Conclusive proof that gemcitabine is also extensively absorbed in 
human is not possible without direct testing in human subjects. However, insights into translating 
our findings in mice to human could be gained by future work exploring the intestinal expression 
of nucleoside transporters in mice and human on a protein level, as well as potential differences in 
gemcitabine transport by orthologous proteins (e.g., human ENT1 vs. mouse ENT1). Such 
information could be incorporated into a physiologically-based pharmacokinetic (PBPK) model of 
gemcitabine intestinal absorption, better enabling more accurate quantitative predictions of 
gemcitabine absorption in human. 
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 The results presented in Chapter 3 also suggest that gemcitabine’s oral bioavailability in 
human could be greatly increased by co-administration with a cytidine deaminase inhibitor. This 
conclusion is in accordance with previous work in mice showing that co-administration of a 
cytidine deaminase inhibitor increases gemcitabine’s oral bioavailability approximately 4-fold. 
Importantly, our results further suggest that the fraction of drug absorbed from the intestinal lumen 
will decrease with increasing dose as uptake via nucleoside transporters becomes saturated. Thus, 
if this formulation strategy is pursued, gemcitabine may need to be administered via divided doses 
or given as a controlled-released formulation to limit intestinal drug concentrations (i.e., below 
saturating concentrations) and maximize the fraction of drug absorbed. The hypothesized inverse 
relationship between gemcitabine bioavailability and dose (i.e., bioavailability decreases as dose 
increases) could be tested in mice by determining gemcitabine bioavailability over a range of orally 
administered doses. Additionally, the aforementioned PBPK model of gemcitabine intestinal 
absorption, which reflects the dynamic nature of drug absorption (i.e., drug concentrations in the 
intestinal lumen decrease as drug is absorbed), could provide insights into the relationship between 
dose and fraction absorbed and guide the development of clinical dosing regimens and 
formulations (e.g., controlled-release) with acceptable intestinal absorption.  
 Another strategy to increase gemcitabine’s oral bioavailability, formulating gemcitabine as 
the peptide transporter 1 (PEPT1)-targeted amino acid ester prodrug 5’-L-valyl-gemictabine (V-
Gem), was explored in this dissertation (Chapter 4). Oral V-Gem administration did not increase 
gemcitabine systemic exposure, relative to oral gemcitabine administration, due, in large part, to 
extensive V-Gem activation in intestinal epithelial cells. Thus, future work developing 
gemcitabine prodrugs for oral administration should focus on prodrugs which have higher 
presystemic stability while maintaining adequate intestinal permeability. Importantly, however, 
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such prodrugs must not be so stable that they are resistant to subsequent systemic activation. This 
balance between the prodrug’s presystemic stability and systemic activation can be manipulated 
by changing the amino acid moiety in the PEPT1-targeted amino acid ester prodrug (e.g., 5’-L-
phenylalanly-gemcitabine), the linkage between the amino acid and gemcitabine (e.g., amino acid 
amide prodrug), or by changing the prodrug type completely (e.g., a prodrug not targeted to 
PEPT1).  
 The results presented in Chapter 4 further suggest that V-Gem may not be completely 
activated to gemcitabine (i.e., V-Gem is directly converted to both gemcitabine and another V-
Gem metabolite(s)) following intravenous administration. Confirmation of this hypothesis would 
require verification that additional V-Gem metabolite(s) are formed in vivo. Given our theory that 
V-Gem may be directly deaminated, forming valine-dFdU (V-dFdU), plasma samples collected 
following V-Gem intravenous administration could be analyzed for V-dFdU. Alternatively, a study 
could be performed in which radiolabeled V-Gem (e.g., [3H] or [14C]) is intravenously 
administered and drug-related metabolites are identified and quantified in plasma. While 
synthesizing radiolabeled V-Gem would likely be resource intensive, such a radiolabeled study 
would greatly ease identification of potential V-Gem metabolites. Furthermore, similar studies 
could be conducted to explore V-Gem activation following oral administration as V-Gem 
metabolism may differ following oral and intravenous administration.  
 Finally, given the large gemcitabine doses administered intravenously (1,000 – 1,250 
mg/m2) and the associated high maximum plasma concentrations (≈ 70 µM), it is possible that this 
intravenous pharmacokinetic profile will not be able to be replicated when gemcitabine is 
administered orally. In this case, if gemcitabine is to be administered orally, optimization of the 
pharmacokinetic profile, and thus the dosing regimen, would be required. Furthermore, even if the 
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intravenous pharmacokinetic profile is able to be replicated with an oral formulation, there is 
evidence suggesting that gemcitabine’s efficacy and toxicity may be improved by pharmacokinetic 
profiles often seen with orally administered medications (e.g., sustained plasma exposure at lower 
concentrations). Given that gemcitabine is only administered to patients intravenously, additional 
clinical data on the efficacy and toxicity of the pharmacokinetics associated with such dosing 
regimens would be required.  
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APPENDICES 
 
APPENDIX A 
Individual Data from Chapter 3 
 
Table A.1 The in situ jejunal permeability of gemcitabine at 100 µM in C57BL/6 and BALB/c 
mice when samples were analyzed by UPLC (following experiments performed in C57BL/6 and 
BALB/c mice) and by measuring radioactivity (following experiments performed in C57BL/6 
mice) 
 
Replicate # Strain Analytical Method Peff (x 10
-4 cm/s) Perfused Segment Length (cm) 
1 C57BL/6 UPLC 1.18 ± 0.08 5.5 
2 C57BL/6 UPLC 1.05 ± 0.05 5.5 
3 C57BL/6 UPLC 0.97 ± 0.08 9 
4 C57BL/6 UPLC 1.35 ± 0.05 9 
AVERAGE C57BL/6 UPLC 1.14 ± 0.17  
     
1 C57BL/6 Radioactivity 1.18 ± 0.10 7.5 
2 C57BL/6 Radioactivity 0.76 ± 0.13 5.5 
3 C57BL/6 Radioactivity 1.19 ± 0.15 7.5 
4 C57BL/6 Radioactivity 1.09 ± 0.08 6.5 
AVERAGE C57BL/6 Radioactivity 1.05 ± 0.20  
     
1 BALB/c UPLC 1.22 * 5 
2 BALB/c UPLC 0.97 ± 0.14 6 
AVERAGE BALB/c UPLC 1.09 ± 0.18  
 
Data are presented as mean ± SD. For each replicate, the mean and SD were calculated using the 
permeability values determined at each of the six sampling timepoints. The average mean and SD 
were calculated using the means of the individual replicates. *Individual SD unavailable. Peff, in 
situ jejunal permeability 
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Table A.2 Concentration-dependent gemcitabine permeability and flux during in situ jejunal 
perfusions in C57BL/6 mice 
 
Replicate # Concentration (µM) 
Peff (x 10-4 
cm/s) 
Flux 
(pmol/cm2/s) 
Perfused 
Segment 
Length (cm) 
1 0.5 2.20 ± 0.25 0.110 ± 0.013 7 
2 0.5 1.65 ± 0.14 0.082 ± 0.007 6.5 
3 0.5 1.66 ± 0.06 0.083 ± 0.003 8 
4 0.5 1.19 ± 0.27 0.058 ± 0.013 8 
AVERAGE 0.5 1.68 ± 0.41 0.084 ± 0.021  
     
1 1 1.45 ± 0.13 0.145 ± 0.013 7.5 
2 1 1.56 ± 0.18 0.156 ± 0.018 7 
3 1 1.63 ± 0.04 0.163 ± 0.004 6.5 
4 1 1.75 ± 0.11 0.175 ± 0.011 6.5 
AVERAGE 1 1.60 ± 0.12 0.160 ± 0.012  
     
1 5 1.40 ± 0.12 0.701 ± 0.059 7 
2 5 2.20 ± 0.12 1.10 ± 0.06 6 
3 5 2.18 ± 0.10 1.09 ± 0.05 5.5 
4 5 1.67 ± 0.08 0.834 ± 0.040 6 
AVERAGE 5 1.86 ± 0.39 0.931 ± 0.197  
     
1 10 1.75 ± 0.13 1.75 ± 0.13 6 
2 10 1.74 ± 0.03 1.74 ± 0.03 6 
3 10 1.88 ± 0.09 1.88 ± 0.09 5 
4 10 1.47 ± 0.12 1.47 ± 0.12 8 
AVERAGE 10 1.71 ± 0.17 1.71 ± 0.17  
     
1 25 1.06 ± 0.09 2.66 ± 0.23 6 
2 25 0.72 ± 0.02 1.79 ± 0.05 5 
3 25 1.34 ± 0.14 3.36 ± 0.35 7 
4 25 1.23 ± 0.03 3.04 ± 0.08 6.5 
AVERAGE 25 1.09 ± 0.27 2.71 ± 0.68  
     
1 50 0.78 ± 0.05 3.91 ± 0.25 6.5 
2 50 1.20 ± 0.08 6.00 ± 0.39 6.5 
3 50 1.11 ± 0.05 5.56 ± 0.25 6 
4 50 0.85 ± 0.07 4.24 ± 0.36 7.5 
AVERAGE 50 0.985 ± 0.201 4.92 ± 1.01  
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1 75 0.835 ± 0.026 6.26 ± 0.20 6.5 
2 75 0.684 ± 0.043 5.13 ± 0.32 6.5 
3 75 0.842 ± 0.071 6.31 ± 0.53 7 
4 75 0.714 ± 0.060 5.35 ± 0.45 7.5 
AVERAGE 75 0.769 ± 0.081 5.76 ± 0.61  
     
1 100 0.831 ± 0.110 8.31 ± 1.10 6 
2 100 0.692 ± 0.036 6.92 ± 0.36 6 
3 100 0.761 ± 0.063 7.61 ± 0.63 6 
4 100 0.743 ± 0.040 7.43 ± 0.40 6 
AVERAGE 100 0.757 ± 0.058 7.57 ± 0.58  
     
1 150 0.498 ± 0.022 7.46 ± 0.34 6.5 
2 150 0.520 ± 0.031 7.80 ± 0.46 7 
3 150 0.598 ± 0.058 8.97 ± 0.87 7 
4 150 0.500 ± 0.067 7.49 ± 1.01 6.5 
AVERAGE 150 0.529 ± 0.047 7.93 ± 0.71  
     
1 250 0.427 ± 0.039 10.68 ± 0.98 5.5 
2 250 0.519 ± 0.043 12.98 ± 1.08 7 
3 250 0.485 ± 0.049 12.14 ± 1.22 6.5 
4 250 0.623 ± 0.077 15.57 ± 1.91 4 
AVERAGE 250 0.514 ± 0.082 12.84 ± 2.05  
     
1 500 0.344 ± 0.060 17.19 ± 2.98 7.5 
2 500 0.431 ± 0.028 21.56 ± 1.42 6 
3 500 0.418 ± 0.114 20.90 ± 5.71 6 
4 500 0.425 ± 0.022 21.25 ± 1.10 6 
AVERAGE 500 0.404 ± 0.041 20.22 ± 2.04  
     
1 750 0.297 ± 0.141 22.26 ± 10.60 7 
2 750 0.263 ± 0.096 19.71 ± 7.17 7 
3 750 0.416 ± 0.141 31.21 ± 10.58 7 
4 750 0.402 ± 0.162 30.16 ± 12.17 6.5 
AVERAGE 750 0.344 ± 0.076 25.83 ± 5.72  
     
1 1250 0.192 ± 0.131 23.97 ± 16.31 6 
2 1250 0.197 ± 0.053 24.58 ± 6.68 6.5 
3 1250 0.199 ± 0.112 24.90 ± 13.97 6.5 
4 1250 0.129 ± 0.019 16.08 ± 2.35 6.5 
AVERAGE 1250 0.179 ± 0.034 22.38 ± 4.22  
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1 2000 0.185 ± 0.026 36.91 ± 5.17 6 
2 2000 0.102 ± 0.087 20.46 ± 17.39 6 
3 2000 0.230 ± 0.083 46.02 ± 16.69 7 
4 2000 0.081 ± 0.016 16.27 ± 3.16 8 
AVERAGE 2000 0.150 ± 0.070 29.91 ± 13.95  
 
Data are presented as mean ± SD. For individual replicates, mean and SD were calculated using 
the permeability values determined at each of the six sampling timepoints. The average mean and 
SD were calculated using the means of the individual replicates. Peff, in situ jejunal permeability   
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Table A.3 Effect of co-perfused nucleoside transporter inhibitors on the in situ jejunal 
permeability of 5 µM gemcitabine in C57BL/6 mice  
Replicate # Inhibitor Peff (x 10-4 cm/s) Perfused Segment Length (cm) 
1 None 1.40 ± 0.12 7 
2 None 2.20 ± 0.12 6 
3 None 2.18 ± 0.10 5.5 
4 None 1.67 ± 0.08 6 
AVERAGE None 1.86 ± 0.39  
    
1 2 mM thymidine 0.0056 ± 0.0032 7 
2 2 mM thymidine 0.0117 ± 0.0012 7 
3 2 mM thymidine 0.0101 ± 0.0019 6 
4 2 mM thymidine 0.0066 ± 0.0048 6.5 
AVERAGE 2 mM thymidine 0.0085 ± 0.0029  
    
1 Na+-free buffer 0.055 ± 0.007 7.5 
2 Na+-free buffer 0.065 ± 0.010 6.5 
3 Na+-free buffer 0.070 ± 0.008 6 
4 Na+-free buffer 0.048 ± 0.009 6.5 
AVERAGE Na+-free buffer 0.059 ± 0.010  
    
    
Replicate # Inhibitor Peff (x 10-4 cm/s) Perfused Segment Length (cm) 
1 None 1.46 ± 0.06 7.5 
2 None 1.48 ± 0.08 6.5 
3 None 1.42 ± 0.07 8 
4 None 1.50 ± 0.11 7 
AVERAGE None 1.47 ± 0.04  
    
1 2 mM dilazep 0.78 ± 0.16 7.5 
2 2 mM dilazep 0.73 ± 0.07 7.5 
3 2 mM dilazep 0.61 ± 0.06 7 
4 2 mM dilazep 0.82 ± 0.16 5.5 
AVERAGE 2 mM dilazep 0.74 ± 0.09  
 
Data are presented as mean ± SD. For individual replicates, mean and SD were calculated using 
the permeability values determined at each of the six sampling timepoints. The average mean and 
SD were calculated using the means of the individual replicates. Experiments with 2 mM 
thymidine and sodium-free buffer were performed months before those with 2 mM dilazep and, as 
a result, control values were reported for each set of experiments. Peff, in situ jejunal permeability.   
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Table A.4 Total radioactivity in jejunal tissue and portal venous plasma following in situ jejunal 
perfusion of 5 µM [14C]-gemcitabine in C57BL/6 mice  
 
Replicate # Inhibitor 
Jejunal Tissue 
Gemcitabine 
Equivalents 
(pmol)/ mg tissue 
Plasma Gemcitabine 
Equivalents 
(pmol)/ mL plasma 
Perfused 
Segment 
Length (cm) 
1 None 10.7 955.2 7.5 
2 None 10.2 694.9 6.5 
3 None 9.6 674.6 8 
4 None 7.5 728.4 7 
AVERAGE None 9.52 ± 1.41 763.3 ± 129.9  
     
1 2 mM dilazep 10.7 213.8 7.5 
2 2 mM dilazep 11.0 318.7 7.5 
3 2 mM dilazep 8.3 229.9 7 
4 2 mM dilazep 8.7 229.4 5.5 
AVERAGE 2 mM dilazep 9.67 ± 1.36 248.0 ± 47.8  
 
Data are presented as mean ± SD. 
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Table A.5 Concentration-dependent thymidine- and dilazep-mediated inhibition of gemcitabine 
flux during in situ jejunal perfusion of 5 µM gemcitabine in C57BL/6 mice  
 
Inhibitor 
Inhibitor 
Concentration 
(µM) 
Gemcitabine Flux 
(pmol/cm2/s) 
% of 
control 
Thymidine 0 0.809 100.0 
Thymidine 0.1 0.890 110.0 
Thymidine 1 0.759 93.8 
Thymidine 10 0.616 76.2 
Thymidine 100 0.395 48.8 
Thymidine 200 0.249 30.8 
Thymidine 300 0.280 34.6 
Thymidine 1000 0.081 10.0 
Thymidine 2000 0.043 5.3 
    
Dilazep 0 0.809 100.0 
Dilazep 0.1 0.820 101.4 
Dilazep 1 0.646 79.8 
Dilazep 1 0.630 77.9 
Dilazep 10 0.811 100.2 
Dilazep 50 0.769 95.0 
Dilazep 100 0.593 73.2 
Dilazep 500 0.506 62.5 
Dilazep 1000 0.476 58.9 
Dilazep 2000 0.368 45.5 
Dilazep 2500 0.364 45.0 
 
Data are presented as mean (n = 1-4).  
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APPENDIX B 
Individual Data from Chapter 4 
 
Table B.1 The plasma concentration – time profiles of gemcitabine and dFdU in C57BL/6 mice 
following intravenous gemcitabine administration 
 
 ID = GEMIV-WTF1 ID = GEMIV-WTF2 
Time(min) Gem (µM) dFdU (µM) 
Gem 
(µM) dFdU (µM) 
2 47.1 8.87 58.2 6.22 
5 37.6 10.6 41.7 9.80 
15 23.5 17.3 34.4 15.9 
30 12.3 22.2 15.8 18.1 
45 7.40 22.0 10.8 18.9 
60 4.41 20.2 7.38 16.6 
90 1.27 17.4 2.40 12.7 
120 0.551 13.2 0.814 10.3 
180 0.407 9.11 0.261 6.30 
240 0.126 6.37 0.146 4.43 
300 0.160 5.38 0.075 2.66 
360 0.057 4.98 BQL 1.84 
 
 
 
 
 
 
 
 
 
 
 
Gem, gemcitabine; dFdU, 2’,2’-difluorodeoxyuridine; AQL, above the limit of quantification; 
BQL, below the limit of quantification  
 ID = GEMIV-WTM1 ID = GEMIV-WTM2 
Time(min) Gem (µM) dFdU (µM) 
Gem 
(µM) dFdU (µM) 
2 47.3 4.02 AQL 7.73 
5 41.1 5.83 82.8 9.19 
15 24.4 9.93 58.6 12.2 
30 14.6 11.3 33.3 11.0 
45 8.41 10.7 13.2 9.55 
60 5.18 9.8 9.46 7.13 
90 1.62 6.63 4.34 4.76 
120 0.657 4.84 1.43 2.34 
180 0.162 2.31 0.464 1.36 
240 0.0714 1.64 BQL 0.819 
300 BQL 0.881 BQL 0.515 
360 BQL 0.66 BQL BQL 
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Table B.2 Non-compartmental analysis of the gemcitabine and dFdU plasma concentration-time 
profiles in C57BL/6 mice following intravenous gemcitabine administration 
 
ID 
AUC0-6 hr 
(min x 
µM) 
AUCinf 
(min x 
µM) 
% 
Extrapolated 
T1/2 
(min) 
Tmax 
(min) 
Cmax 
(µM) 
CL 
(mL/hr/g) 
Vss 
(mL/g) Analyte 
GEMIV-
WTF1 1211.5 1217.1 0.5% 67.2 - 54.7* 3.75 2.10 
Gem  
GEMIV-
WTF2 1619.6 1625.4 0.4% 53.8 - 72.7* 2.81 1.47 
GEMIV-
WTM1 1294.1 1297.5 0.3% 33.4 - 51.9* 3.51 1.65 
GEMIV-
WTM2 2718.4 2736.5 0.7% 27.1 - 98.4* 1.67 0.78 
          
GEMIV-
WTF1 3941.8 5148.5 23.4% 168.0 30.0 22.2 - - 
dFdU 
GEMIV-
WTF2 2909.6 3165.9 8.1% 96.6 45.0 18.9 - - 
GEMIV-
WTM1 1448.9 1539.3 5.9% 95.0 30.0 11.3 - - 
GEMIV-
WTM2 1455.5 1516.7 4.0% 82.4 30.0 12.2 - - 
 
*C0 (initial plasma concentration) reported. Gem, gemcitabine; dFdU, 2’,2’-difluorodeoxyuridine; 
AUC0-6hr, area under the plasma concentration-time curve from time 0 to 6 hr; AUCinf, area under 
the plasma concentration-time curve from time 0 to infinity; T1/2, terminal half-life; Tmax, time of 
maximum plasma concentration; Cmax, maximum plasma concentration; CL, clearance; Vss, volume 
of distribution at steady-state 
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Table B.3 The plasma concentration – time profiles of gemcitabine and dFdU in C57BL/6 mice 
following oral gemcitabine administration 
 
 ID = GEMPO-WTF1 ID = GEMPO-WTF2 
Time(min) Gem (µM) dFdU (µM) 
Gem 
(µM) dFdU (µM) 
2 3.59 4.85 1.39 2.33 
5 6.67 10.9 3.06 6.57 
15 13.6 29.4 6.06 17.2 
30 13.9 39.4 5.90 25.3 
45 12.8 40.6 4.89 24.8 
60 10.3 37.3 5.06 24.6 
90 3.77 26.3 2.21 20.4 
120 0.991 19.6 0.703 19.7 
180 0.148 13.1 0.151 16.1 
240 BQL 10.4 BQL 15.9 
300 BQL 9.53 BQL 13.1 
360 BQL 8.68 BQL 10.2 
 
 ID = GEMPO-WTM1 ID = GEMPO-WTM2 
Time(min) Gem (µM) dFdU (µM) Gem (µM) 
dFdU  
(µM) 
2 0.990 1.64 2.03 2.55 
5 1.96 4.78 3.06 4.44 
15 5.51 12.9 8.75 16.4 
30 8.00 25.8 13.1 31.1 
45 7.97 30.9 13.4 37.2 
60 6.48 30.0 11.4 35.9 
90 4.60 23.3 7.64 30.1 
120 2.67 16.2 10.6 49.1 
180 0.551 11.1 1.93 15.4 
240 0.188 8.22 0.381 7.98 
300 0.118 7.79 0.184 6.28 
360 BQL 5.85 0.103 5.94 
 
Gem, gemcitabine; dFdU, 2’,2’-difluorodeoxyuridine; BQL, below the limit of quantification 
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Table B.4 Non-compartmental analysis of the gemcitabine and dFdU plasma concentration-time 
profiles in C57BL/6 mice following oral gemcitabine administration 
 
ID 
AUC0-6 hr 
(min x 
µM) 
AUCinf 
(min x 
µM) 
% 
Extrapolated 
T1/2 
(min) 
Tmax 
(min) 
Cmax 
(µM) 
CL/F 
(mL/hr/g) Analyte 
GEMPO
-WTF1 1016.7 1020.9 0.4% 19.4 30.0 13.9 13.4 
Gem  
GEMPO
-WTF2 477.3 482.4 1.1% 23.4 15.0 6.1 28.4 
GEMPO
-WTM1 775.5 782.3 0.9% 39.9 30.0 8.0 17.5 
GEMPO
-WTM2 1647.3 1653.8 0.4% 43.7 45.0 13.4 8.3 
         
GEMPO
-WTF1 6402.9 10342.0 38.1% 314.6 45.0 40.6 - 
dFdU 
GEMPO
-WTF2 6079.0 9994.6 39.2% 266.1 30.0 25.3 - 
GEMPO
-WTM1 4952.0 6419.9 22.9% 173.9 45.0 30.9 - 
GEMPO
-WTM2 7142.8 8293.4 13.9% 134.3 120.0 49.1 - 
 
Gem, gemcitabine; dFdU, 2’,2’-difluorodeoxyuridine; AUC0-6hr, area under the plasma 
concentration-time curve from time 0 to 6 hr; AUCinf, area under the plasma concentration-time 
curve from time 0 to infinity; T1/2, terminal half-life; Tmax, time of maximum plasma concentration; 
Cmax, maximum plasma concentration; CL/F, oral clearance  
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Table B.5 The plasma concentration – time profiles of 5’-L-valyl-gemictabine, gemcitabine, and 
dFdU in C57BL/6 mice following intravenous 5’-L-valyl-gemictabine administration 
 
 ID =PDIV-WTF1 ID =PDIV-WTF2 
Time(min) V-Gem (µM) 
Gem 
(µM) 
dFdU 
(µM) 
V-Gem 
(µM) 
Gem 
(µM) 
dFdU 
(µM) 
2 7.97 40.7 10.9 13.6 38.8 13.9 
5 2.62 31.0 13.7 2.94 25.2 17.4 
15 0.577 13.5 14.6 0.259 13.4 20.0 
30 0.0856 6.7 14.9 BQL 6.14 19.1 
45 BQL 3.02 14.8 BQL 3.02 18.6 
60 BQL 1.33 13.2 BQL 1.66 17.1 
90 BQL 0.537 12.0 BQL 0.394 14.2 
120 BQL 0.304 10.3 BQL 0.202 10.6 
180 BQL 0.184 6.25 BQL 0.174 6.34 
240 BQL 0.113 4.67 BQL BQL 4.08 
300 BQL BQL 3.19 BQL BQL 3.24 
360 BQL BQL 3.35 BQL BQL 2.95 
 
 ID =PDIV-WTM1 ID =PDIV-WTM2 
Time(min) V-Gem (µM) 
Gem 
(µM) 
dFdU 
(µM) 
V-Gem 
(µM) 
Gem 
(µM) 
dFdU 
(µM) 
2 48.8 58.7 7.11 7.68 32.2 7.55 
5 10.8 38.2 10.3 3.25 25.8 8.52 
15 1.71 18.6 11.7 0.738 16.4 9.80 
30 0.134 10.5 12.7 BQL 9.39 9.57 
45 BQL 6.37 11.5 BQL 6.89 8.97 
60 BQL 3.39 11.9 BQL 4.18 7.66 
90 BQL 0.682 6.82 BQL 1.88 5.75 
120 BQL 0.477 4.38 BQL 0.738 3.73 
180 BQL 0.211 2.08 BQL 0.218 1.93 
240 BQL 0.051 0.943 BQL 0.0510 0.840 
300 BQL BQL 1.07 BQL 0.0721 0.768 
360 BQL BQL 0.781 BQL BQL 0.548 
 
V-Gem, 5’-L-valyl-gemcitabine; Gem, gemcitabine; dFdU, 2’,2’-difluorodeoxyuridine; BQL, 
below the limit of quantification  
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Table B.6 Non-compartmental analysis of the 5’-L-valyl-gemcitabine, gemcitabine, and dFdU 
plasma concentration-time profiles in C57BL/6 mice following intravenous 5’-L-valyl-
gemcitabine administration 
 
ID 
AUC0-6 hr 
(min x 
µM) 
AUCinf 
(min x 
µM) 
% 
Extrapolated 
T1/2 
(min) 
Tmax 
(min) 
Cmax 
(µM) 
CL 
(mL/hr/g) 
Vss 
(mL/g) Analyte 
PDIV-
WTF1 61.5 62.2 1.0% 5.1 - 16.7* 73.3 5.43 
V-Gem 
PDIV-
WTF2 92.2 93.1 1.0% 2.4 - 37.8* 49.0 1.75 
PDIV-
WTM1 348.0 348.7 0.2% 4.0 - 133.4* 13.1 0.61 
PDIV-
WTM2 57.6 61.9 6.9% 4.0 - 13.6* 73.6 5.72 
          
PDIV-
WTF1 691.6 703.1 1.6% 70.1 2 40.7 - - 
Gem 
PDIV-
WTF2 629.2 637.3 1.3% 32.4 2 38.8 - - 
PDIV-
WTM1 1013.0 1016.0 0.3% 40.5 2 58.7 - - 
PDIV-
WTM2 899.4 904.5 0.6% 49.3 2 32.2 - - 
          
PDIV-
WTF1 2811.9 3704.4 24.1% 184.7 30 14.9 - - 
dFdU 
PDIV-
WTF2 3159.2 3860.0 18.2% 164.7 15 20.0 - - 
PDIV-
WTM1 1532.4 1646.4 6.9% 101.1 30 12.7 - - 
PDIV-
WTM2 1216.3 1285.4 5.4% 87.4 15 9.8 - - 
 
*C0 (initial plasma concentration) reported. V-Gem, 5’-L-valyl-gemcitabine; Gem, gemcitabine; 
dFdU, 2’,2’-difluorodeoxyuridine; AUC0-6hr, area under the plasma concentration-time curve from 
time 0 to 6 hr; AUCinf, area under the plasma concentration-time curve from time 0 to infinity; 
T1/2, terminal half-life; Tmax, time of maximum plasma concentration; Cmax, maximum plasma 
concentration; CL, clearance; Vss, volume of distribution at steady-state  
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Table B.7 The plasma concentration – time profiles of 5’-L-valyl-gemictabine, gemcitabine, and 
dFdU in C57BL/6 mice following oral 5’-L-valyl-gemictabine administration 
 
 ID =PDPO-WTF1 ID =PDPO-WTF2 
Time(min) V-Gem (µM) 
Gem 
(µM) 
dFdU 
(µM) 
V-Gem 
(µM) 
Gem 
(µM) 
dFdU 
(µM) 
2 0.261 3.22 4.40 0.168 5.71 12.4 
5 0.297 7.93 16.9 0.309 11.6 27.5 
15 0.0708 10.9 39.3 BQL 10.8 46.6 
30 0.0908 10.7 49.9 BQL 6.71 38.7 
45 BQL 10.1 49.7 BQL 6.03 39.3 
60 BQL 8.69 48.1 BQL 3.57 29.8 
90 BQL 4.97 35.4 BQL 1.02 22.5 
120 BQL 2.18 25.1 BQL 0.401 16.7 
180 BQL 0.434 18.1 BQL 0.104 11.1 
240 BQL 0.140 18.9 BQL BQL 8.81 
300 BQL 0.146 14.4 BQL BQL 7.21 
360 BQL BQL 12.0 BQL BQL 7.13 
 
 ID =PDPO-WTM1 ID =PDPO-WTM2 
Time(min) V-Gem (µM) 
Gem 
(µM) 
dFdU 
(µM) 
V-Gem 
(µM) 
Gem 
(µM) 
dFdU 
(µM) 
2 0.528 5.03 7.86 0.0741 1.25 2.43 
5 0.405 10.2 20.9 0.0510 2.68 7.83 
15 0.0753 14.6 46.6 0.0722 7.75 28.2 
30 BQL 10.2 50.9 BQL 8.29 44.4 
45 BQL 8.08 48.9 BQL 6.25 44.4 
60 BQL 5.67 46.1 BQL 4.98 41.1 
90 BQL 3.15 34.3 BQL 2.82 32.0 
120 BQL 2.03 27.3 BQL 2.16 24.3 
180 BQL 1.11 18.2 BQL 1.91 18.8 
240 BQL 0.300 12.4 BQL 0.997 15.1 
300 BQL 0.152 15.1 BQL 0.373 13.4 
360 BQL BQL 14.6 BQL 0.130 10.8 
 
V-Gem, 5’-L-valyl-gemcitabine; Gem, gemcitabine; dFdU, 2’,2’-difluorodeoxyuridine; BQL, 
below the limit of quantification  
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Table B.8 Non-compartmental analysis of the 5’-L-valyl-gemcitabine, gemcitabine, and dFdU 
plasma concentration-time profiles in C57BL/6 mice following oral 5’-L-valyl-gemcitabine 
administration 
 
ID 
AUC0-6 hr 
(min x 
µM) 
AUCinf 
(min x 
µM) 
% 
Extrapolated 
T1/2 
(min) 
Tmax 
(min) 
Cmax 
(µM) Analyte 
GEMPO-
WTF1 4.15 CND CND CND 5 0.30 
V-Gem 
GEMPO-
WTF2 0.88 CND CND CND 5 0.31 
GEMPO-
WTM1 4.33 CND CND CND 2 0.53 
GEMPO-
WTM2 0.88 CND CND CND 2 0.07 
        
GEMPO-
WTF1 989.4 997.6 0.8% 38.9 15 10.9 
Gem 
GEMPO-
WTF2 547.9 552.0 0.8% 27.8 5 11.6 
GEMPO-
WTM1 938.2 948.4 1.1% 46.8 15 14.6 
GEMPO-
WTM2 830.1 838.7 1.0% 46.0 30 8.3 
        
GEMPO-
WTF1 8823.9 13047.7 32.4% 244.0 30 49.9 
dFdU 
GEMPO-
WTF2 5900.4 7905.3 25.4% 194.9 15 46.6 
GEMPO-
WTM1 8709.8 13273.4 34.4% 216.7 30 50.9 
GEMPO-
WTM2 7881.7 11187.1 29.5% 212.1 30 44.4 
 
V-Gem, 5’-L-valyl-gemcitabine; Gem, gemcitabine; dFdU, 2’,2’-difluorodeoxyuridine; CND, 
could not be determined; AUC0-6hr, area under the plasma concentration-time curve from time 0 to 
6 hr; AUCinf, area under the plasma concentration-time curve from time 0 to infinity; T1/2, terminal 
half-life; Tmax, time of maximum plasma concentration; Cmax, maximum plasma concentration 
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APPENDIX C 
Mechanisms of Gemcitabine Oral Absorption as Determined by In Situ Intestinal 
Perfusions in Mice 
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APPENDIX D 
Pharmacokinetics of Gemcitabine and its Amino Acid Ester Prodrug following 
Intravenous and Oral Administrations in Mice 
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APPENDIX E 
Chemoproteomic Identification of Serine Hydrolase RBBP9 as a Valacyclovir-
Activating Enzyme 
 
